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CHAPTER I 
SOMATOSTATIN, BIOLOGY AND CLINICAL APPLICATIONS 
9 
Bwlogy 
Somatostatin was isolated and characterized by investigators working in the laboratory 
of Guillemin at the Salk Institute in La Jolla, California in 1973 during a search for a growth 
hormone (GR, somatotropin) releasing factor in sheep hypothalamus, since physiological , 
experimental, and clinical observations had led to the concept that the hypothalamus controls 
and regulates the secretion of GR by the pituitary gland"'- They observed that the addition 
of crude hypothalamic extracts in minute concentrations to the incubation medium of 
dispersed rat pituitary cell s in monolayer cultures significantly decreases the basal secretion 
of immunoreactive GR' . This inhibition was related to the dose of hypothalaJl)ic extract added 
and was specific. They decided to attribute this inhibitory effect on the secretion of GR to 
a "somatotropin-release inhibiting factor'" (SRIF) or somatostatin (SS). After the isolation of 
the postulated SS from the hypothalamic extracts, quantitative amino acid analysis and 
sequence determination , the primary structure of SS was characterized'. SS was found to be 
a tetradecapeptide (SS- 14) with a disulphide bridge connecting both cysteine molecules (fig.I): 
H -Ala-GI y-Cys-L ys-Asn-Phe-Phe-Trp-L ys-Thr -Phe-Thr-Ser-Cys-OR 
Figure I. 
Somatostarin. 
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Several groupS'"' synthesized SS after the structure of this tetrapeptide was established 
and its in vitro effects (eg.GH release inhibition) were confirmed in rat pituitaries. Since the 
primary structure of native porcine and sheep SS were identical, this suggested that SS also 
exists in other species. 
It is now clear that SS is also widely distributed in the human body, being found first 
in high concentrations in the hypothalamus, later on it was discovered in other areas of the 
brain, thyroid, thymus, bronchi, in the stomach (antrum, corpus and fundus), the pancreas 
and the intestines. More than 90% of SS immunoreactivity in the human gut is present within 
mucosal endocrine cells. SS in the pancreas is located in the D cells at the periphery of the 
islets of Langerhans'"12 
After the identification and purification of SS-14, precursor forms of greater molecular 
weight have been recognized'·lo.!'. Somatostatin-28 (SS-28), or prosomatostatin, is a 28-amino 
acid polypeptide with SS-14 making up the C-terminus'. 
H -Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met -Ala-Pro-Arg -Gl u-Arg -L ys-
Ala-Gl y-Cys-L ys-Asn-Phe-Phe-Trp-L ys-Thr-Phe-Thr-Ser-Cys-O 
This larger molecular form can be converted into the smaller SS-14 by a processing enzyme 
found in the mouse hypothalamusl'. Preprosomatostatins are even larger precursor forms of 
120 or more amino acids, with SS-28 located at the C-terminuslO • All of these different forms 
exert biologic activity but they differ in their relative potencyl'. 
Various studies demonstrated mainly inhibitory effects of SS-14. These include 
inhibition of GH and thyroid stimulating hormone (TSH) release by the anterior pituitary 
gland1.16, inhibition of endocrine (insulin, glucagon) and exocrine pancreatic function and of 
gastrin release17-22 . 
The degree of inhibition of GH secretion by SS is determined by two critical factors: 
the concentration of the peptide in the hypothalamic portal plasma and the number of SS 
receptors (SS-R's) on the anterior pituitary gland. 
The effects of SS are believed to modulate the GH responses to GH-releasing hormone 
(GHRH) secretion in the generation of pulsatile GH secretion"·24. The suppression of TSH 
is of a lesser degree as compared with that of GH. This may be explained by the differences 
in SS-R's on the GH and TSH producing cells in the anterior pituitary gland"'''. 
Because large numbers of SS-R's are also present on most GH-secreting pituitary 
adenomas in acromegalic patients", chronic SS analogue therapy causes a marked clinical 
improvement in these patients and the typical soft tissue swelling decreases after weeks27.". 
Tumour shrinkage of the adenoma was found in more than 50% of these patients, which may 
facilitate selective transsphenoidal adenomectomy andlor external pituitary irradiation". 
Although the mechanisms regulating the stimulation of secretion by the exocrine 
pancreas have been extensively studied, little is known about the physiological mechanisms 
involved in inhibition. SS was suggested to act inhibitory directly via specific cell surface 
receptors, because such receptors were identified on isolated guinea pig acinar cells30-32 . 
Numerous studies, however, have failed to demonstrate inhibition by SS of amylase release 
by isolated acini during stimulation with cholecystokinin (CCK), vasoactive intestinal 
polypeptide (VIP), carbachol, or secretin"'''. Also in pancreatic lobule preparations in the 
isolated vascularly perfused pancreas SS was ineffective in inhibiting stimulated secretion". 
In contrast, SS was an effective inhibitor of stimulated exocrine secretion in vivo. This was 
explained by Mulvihill et a!. 35 who postulated the concept that 5S acts indirectly via neural 
mechanisms (tetrodotoxin-sensitive, non-adrenergic, or non-cholinergic pathways). 
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The therapeutic use of SS is impractical because of its multiple actions and the short 
duration of its antisecretory effects; it' s half-l ife in the circulation is about 3 minutes16.17 . 
Studies were carried out by several groups to systematically design and synthesize SS 
analogues with selective enhanced and prolonged activities"-"_ Analogues ofSS-14 and SS-28 
were expensive and not superactive in ViV037.39-42. Therefore Veber et a1.43 carried out 
conformation analysis and designed several analogues by replacing 9 of the 14 amino acids 
of SS with a single proline residue_ However, these hexapeptide analogues, although more 
potent than SS in inhibiting GH, insulin and glucagon release, did not reveal anti tumour 
activities_ Bauer et al'4 synthesized another series of highly potent analogues_ They retained 
Phe-Trp-Lys-Thr and incorporated it with the tryptophan residue in the D configuration, into 
a cysteine-bridged octapeptide analogue (fig.ll) . Thi s analogue, SMS 20 1-995 (Octreotide) 
was long acting and 45-70 times more potent than SS-14 in inhibi ti ng GH secretion and more 
selective, since it suppressed insulin and glucagon to a lesser extent than GH_ Also it did 
show a direct inhibitory effect on tumour growth44-48. 
Figure II. 
Ocrreoride. 
The wide spectrum of gastrointestinal and endocrine actions of SS , mainly inh ibitory in 
nature, are summarized in table 1. 
Table 1. Summary of gastrointesfinal and endocrine activities of somarosrarin. 
Endocrine secretion 
Inhibits secretion of gastrin, secretin, vasoactive intestinal polypeptide (VIP) , 
pancreatic polypeptide, insulin and glucagon 
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Exocrine secretion 
Inhibits secretion of gastric acid and pepsin, pancreatic enzyme and bicarbonate 
production, and intestinal epithelial electrolytes and water release 
Absorptive function 
Motility 
Inhibits absorption of glucose, xylose and amino acids; increases absorption of 
electrolytes and water 
Inhibits motor activity in stomach, small intestine and gallbladder 
Haemodynamics 
Growth 
No effect on cardiac output: decreases coeliac, mesenteric and renal blood flow 
Decreases gastric and intestinal mitotic index and deoxyribonucleic acid 
synthesis; inhibits trophic effect of gastrin 
Clinical application 
Due to the wide spectrum of action, the use of SS has been recently described in the 
treatment of a variety of gastrointestinal disorders, mostly of primary concern to the 
surgeon"'''. Several reports are now available describing the usefulness of SS-14 and/or 
octreotide in controlling upper gastrointestinal haemorrhage, especially that associated with 
portal hypertension51~58. SS-14 and/or octreotide were superior to vasopressin in these studies 
both in the initial control of bleeding, as well as in the number of hospital deaths in patients 
bleeding massively from oesophageal varices"'''. The effectiveness of SS-14 and/or octreotide 
in the treatment of upper gastrointestinal haemorrhage is probably mainly related to its effect 
on mesenteric bloodflow and pressure, but possibly also related to its concomitant 
cytoprotective effects and by the suppression of gastric acid secretion"·6!. 
SS-14 inhibits hormone secretion from both normal and tumorous endocrine gastro-
entero-pancreatic tissue, On the basis of this observation, octreotide has been used in the 
treatment for pancreatic islet cell tumours and carcinoids. Most of these tumours are 
malignant and have already metastasized at the time of diagnosis. These tumours are in 
general slow growing and most of the clinical distress in this type of patients is related to the 
hypersecretion of hormones which often incapacitates them and causes long and repeated 
hospital stays, The clinical use of octreotide in this type of patients is of considerable help 
in controlling clinical symptomatology. Debilitating diarrhoea (VIPoma), peptic ulceration 
(gastrinoma), skin rashes (glucagonoma), hypoglycaemic (insulinoma) and flushing attacks 
(carcinoid) were well controlled during chronic treatment with SS analogues"·64. There is no 
doubt that SS analogue therapy is of great benefit for most of these patients and improve their 
quality of life dramatically"'''-
Clinical trials have been reported demonstrating the effectiveness of octreotide in 
pancreatitis66 . Experimental evidence in animal models supports the usefulness of octreotide 
in pancreatitis: the reduction of exocrine pancreatic secretion by octreotide decreases local 
inflammation and necrosis67.6R . In chronic pancreatitis octreotide is widely tested in ongoing 
trials in Europe. Case reports, however, suggest that octreotide may reduce the size of 
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pseudocysts, while decreasing pain (SJenkins, personal communication). Post pancreatectomy 
complication rates were reduced by intravenous somatostatin69 , and octreotide was similarly 
found to reduce fistula formation, as well as incidence of acute pancreatitis after pancreatic 
surgery"l-72 or pancreatic transplantation7l·". In a well conducted, randomized, double blind, 
placebo controlled, multicenter trial it was found that the perioperative application of 
octreotide reduces the occurrence after pancreatic resection, of postoperative complications 
such as pancreatic fistulas, abscesses and subsequent sepsis, particularly in patients with 
tumours75 . 
Octreotide has few side effects. Ileus with nausea and vomiting has been reported in 
several patients, probable caused by inhibition of normal gastric and intestinal motility. Blood 
sugar levels should be frequently monitored during treatment, especially in type II diabetic 
patients, since octreotide inhibits insulin release and therefore may cause transient 
hyperglycaemia76. Due to its inhibitory effects on cholecystokinin release, gallbladder stones 
may develop during chronic treatment"'''. Only very few allergic reactions have been 
reported''. The safety of its use during pregnancy and lactation has not been determined. 
Since it was known that SS and its analogues interfere with growth factors and possibly 
do have an antiproliferative effect on some tissues, several reports were published about an 
oncological application of octreotide"·". Schally demonstrated in 1987 that the reduction of 
prolactin and GH levels by SS might contribute to the inhibition of the growth of breast and 
prostatic tumours"'''. Another example of an indirect effect of SS through growth factor 
inhibition was postulated after it was noticed that GH stimulates cell differentiation directly 
and clonal expansion indirectly through local production of insulin-like growth factor-I (IGF-
1)85.". On the other hand, preliminary evidence has indicated that SS analogues can selectively 
stimulate the formation of IGF-binding protein I, thereby interfering with IGF-I action at the 
receptor level"'''. SS may also have a direct anti proliferative effect and inhibits DNA 
synthesis and cell replication induced by epidermal growth factor (EGF) in some cells by 
preventing centrosomal separation91 • In human pancreatic cancer cells, SS activates 
dephosphorylation of EGF receptors and thereby reverses the stimulative effect of EGF on 
cell growth37.84,92. 
Another possible mechanism by which SS analogues might inhibit tumour growth is 
interference with the synthesis of autocrine growth factors by tumour cells or by direct 
inhibition of angiogenesis"·93.". Finally a change in natural killer cell activity was reported 
in man" as well as a stimulation of the reticuloendothelial and lymphopoietic system in rats. 
So SS induced changes in immunological activity may explain in part the tumour growth 
inhibitory effece llO 
SOMATOSTATIN RECEPTORS 
After Schonbrunn and Tashjian first measured somatostatin receptors (SS-R's) in 1978 
using the clonal pituitary cell line GH4C", SS-R's have been demonstrated on a variety of 
human tumours, using various iodinated SS analogues in homogenate ligand binding assays 
or autoradiography on tissue sections1m•10l . Large numbers of binding sites with high affinity 
for SS were found on most tumours with amine precursor uptake and decarboxylation 
(APUD) characteristics, as well as on meningiomas, well-differentiated brain tumours 
(astrocytomas), neuroblastomas and human breast tumoursJ02•JJ8 • Examples of tumours with 
APUD characteristics, which are often SS-R positive are, growth-hormone-producing pituitary 
adenomas, endocrine pancreatic tumours, carcinoids, paragangliomas, small cell lung cancers, 
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medullary thyroid carcinomas and pheochromocytomas. In this thesis only the use of SS and 
its analogues in the diagnosis and treatment of breast and pancreatic tumours will be reported . 
Critical to the action of SS is the presence of SS-R's, which like other membrane 
receptors sub serve two functions: (I) to recognize the ligand and bind it with high affinity and 
specificity, and (2) to generate a transmembrane signal that evokes a biological response. 
Three receptor-linked effector systems have been identified"""': (see fig. Ill) 
Figure III. 
(l) Reduerion of rhe inrraeellular mediarors CAMP and Cd· , due ro eifeCls on adenyl 
cyclose and ionic channels (/(', Ca"). 
(2) Acring or a srep distal fO CAMP generarion and Ca'· enrry,rhereby blocking 
hormone seererion srimulared by CAMP and/or Co" ionophores. 
(3) Srimularion o{ryrosine phospharase, leading ro dephosphorylarion and inacrivation 
of ryrosine kinase such as rhose aerivared by (EGF). 
Pharmacological studies have suggested that the distribution of SS-R's is often 
heterogeneous and that there may be selective subtypes for both SS-14 and SS-28. The 
biological activity of the two peptides in general correlates with their potency for receptor 
binding in most systems, suggesting that their selective actions may result mainly from 
differential interaction with receptors13~13' . Reubi et al. have identified pharmacologically SS-
R subtypes in rat and human brain by means of their differential affinity for certain 
somatostatin analogues i36-l3S . 
Recently, at least five different human SS-R types have been cloned. All subtypes bind 
SS-14 and SS-28 with high affinity, while their affinity for octreotide differs considerably. 
Octreotide binds with high affinity to subtype 2 (SSTR,), while this analogue has a relatively 
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low affinity to SSTR, and SSTRs and shows virtually no binding to subtypes 1 and 4 (SSTR1 
and SSTR.)IJ9.142 The cloning of five human SS-R subtypes could provide the molecular basis 
for the mechanisms of regulation by SS of different functions and this may lead to the 
development of selective analogues for a variety of clinical applications. The majority of the 
SS-R positive human tumours expressed the SSTR2 subtype, only a minority of tumours had 
exclusively other SS-R subtypes. One third of the insulinomas, 50% of the receptor positive 
medullary thyroid carcinomas and all SS-R positive ovarian tumours were not of the SSTR2 
typel41 . These SS-R positive tumours may poorly react to treatment with octreotide and they 
cannot be visualized in vivo with radiolabelled octreotide. 
SOMATOSTATIN RECEPTORS IN BREAST CANCER 
Since expression of SS receptors (SS-R's) was a known feature of tumours of the 
nervous system, neuroendocrine tissues and endocrine gastro-intestinal tumours, Papotti et 
al. correlated the expression of neuroendocrine markers in human breast cancer with the 
presence of SS_R'S116, The presence of neuroendocrine cells in normal and in breast cancer 
in man has been a matter of controversy for a long time. As early as 1947, Vogler 
demonstrated argyrophilic cells in normal breast tissuel". Later on Feyrter and Hartmann 
suggested, on the basis of silver impregnation, the endocrine nature of mucoid carcinomas 
("carcinoids") of the human breastl44 . However they were describing myoepithelial cells, 
which were not endocrine, as shown by several histochemical and electron microscopic 
studiesl".!4'. Between 1977 and 1982 several reports demonstrated a variety of argyrophilic 
breast tumours containing dense-core secretory granules and showing the typical features of 
carcinoids. Bussolati et al. also found chromogranin-positive cells immunocytochemically in 
part of human breast cancers with the mouse monoclonal antibody LK2H10 directed against 
human chromogranin 147. Immunoreactivity for neuron-specific enolase, which is present in 
neurons, neuroendocrine cells and tumours with neuroendocrine differentiation, was found 
in more than 30% in breast carcinomas. However, expression of this marker in mammary 
tissues does not appear to be at all related to endocrine differentiation, as defined by 
ultrastructural demonstration of secretory granules. Other markers such as chromogranin A 
and Band synaptophysin were later found to be more specific for neuroendocrine 
differentiation. 
Neuroendocrine differentiation of tumours can be diagnosed on the basis of the 
following morphological and cytochemical criteria: argyrophilia (by Grimelius silver 
staining), presence of secretory granules (by electron microscopy (EM)), and expression of 
specific neuroendocrine markers, such as chromogranin A and B, synapthophysin and neuron-
specific-enolase (NSE). Neuroendocrine differentiation in a subset of human breast 
carcinomas has been suggested in the light of these morphological and cytochemical criteria: 
(a) argyrophilia by Grimelius staining 
(b) secretory granules in EM 
(c) specific neuroendocrine markers 
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Azzopardi et aL 1982148 
Bussolati et aL 1987149 
Cappella et aL 1980ls0 
Nesland et aL 19861sLiS2 
Bussolati et aL 1985, 1987147.149 
Buffa et aL 1988153 
To correlate the existence of neuroendocrine differentiation with the presence of SS-R' s 
in breast carcinomas, Pappoti et al. stained a series of 100 cases with the Grimelius silver 
staining procedure, carried out immunocytochemistry with specific neuroendocrine markers 
and compared the results with that of autoradiography for SS-R'S1l6. A highly significant 
correlation was established between the expression of neuroendocrine markers and high SS-R 
density. This occurred, however, only in 7 of these lOa cases. In a large series Reubi et a1l!4 
evaluated the incidence of SS-R's expression in primary breast tumours. In a group of "small" 
tumour samples with a mean section surface of 14 mm2 , 21 % of the tumours were SS-R 
positive. However in a group of "large" tumour samples with a mean section surface of 180 
mm', 46% were SS-R positive and especially in this group often a non-homogeneous 
distribution was seen, which means that tumour regions within SS-R positive tumours were 
SS-R negative. In their study they also showed that metastases of SS-R positive primary 
tumours may often be SS-R positive1l4 
Binding capacities and apparent dissociation constants for SS-R were determined by 
Fekete et al. in 500 breast biopsy samples using multipoint membrane receptor assays1l5. In 
36% of the tumour samples SS-R's were present and no correlation was found between SS-R 
binding sites and binding capacities of other receptors like oestrogen, progesterone, EGF and 
LH-RH. A negative relationship between the expression of SS-R and EGF receptors in breast 
cancer samples was suggested by Reubi et a1. 114 • 
SOMATOSTATIN RECEPTORS IN PANCREATIC CANCER 
Pancreatic cancer may be divided in endocrine and exocrine tumours, which is based 
on the origin of these tumours. Endocrine pancreatic tumours have neuroendocrine properties, 
which can be confirmed using a combination of immunocytochemical staining with 
chromogranin A and neuron- specific-enolase and the Grimelius silver staining. The origin 
of endocrine pancreatic tumours either from multipotent cells in the ductular epithelium or 
islet cells remains to be established. They are hormone producing tumours, causing several 
clinical syndromes by hypersecretion of these hormones'''''''. After SS-R's have been detected 
on the normal endocrine islet cells (A, Band D cells possess such receptors)!56, Reubi et al. 
demonstrated that most hormone producing endocrine pancreatic tumours also express a high 
density of SS-R' s. Later on it was observed that these receptors were functional, because a 
positive correlation existed between SS-R status of hormone producing endocrine pancreatic 
tumours and the beneficial effect of a stable long-acting SS analogue on hormone release as 
well as growth of these tumours during therapyl57,158. 
Although SS-R have been demonstrated on exocrine pancreatic cells in experimental 
animals mainly in the acinar cells159.161, neither SS-R's nor neuroendocrine properties could 
be found on human exocrine pancreatic adenocarcinomas162 . 
SOMATOSTATIN RECEPTOR SCINTIGRAPHY 
The development of the SS receptor scintigraphy has recently been extensively described 
in the thesis by W.H. Bakker et al.'63 and therefore it will be summarized only briefly. 
First of all Il23 was bound to the SS analogue Tyr'-octreotide (fig.lV) in which Phe has 
been replaced by Tyr in the active site of the molecule to make radio-iodination possible. 
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Figure IV. 
l"s /- Tyr'j -octreolide. 
It was shown that this radioactive analogue was biologically active and bound 
specifically to SS-R's. After it was demonstrated that thi s radioligand could visualize SS-R 
positive tumours in rats after in. vivo administration, it was given iv. to patients suspected to 
have a SS-R expressing tumour. SS-R positive tumours as well as their metastases could be 
visua1ized l 64-166 . 
The clearance of [I"'-Tyr']-octreotide is mainly by the liver and bile. The bowel 
radioactivity makes interpretation of gastrointesti nal tumours in the upper part of the abdomen 
difficult. Also for other technical reasons ("'I is not readily available world-wide, 
radiolabell ing and purification is time consuming, the physical half-life of the radionuclide 
is short and there is rapid clearance from the blood resulting in a short effective residence 
time for accumulation in tumour tissue), ["'In-DTPA-D-Phe']-octreotide (fig. II) was 
developed. 
In contrast to "'I, '''In is readily avai lable and has attractive physical characteristics 
(physical half-life of 2.8 days, gamma emission, which is suitable for scintigraphy with the 
gamma camera). The diethylene-triaminopentaacetic acid (DTPA) had to be coupled to 
octreotide in order to make conjugation of octreotide with l"In possible. [DTPA-D-Phel]-
octreotide binds more than 95% of added " lIn in an easy, single-step labelling procedure 
without necessity of further purification. The specific SS-like biologic effect of these 
analogues was proven by the inhibition of GH secretion by cultured rat pituitary cells in a 
dose-dependent fashion by octreotide, [DTPA-D-Phe']-octreotide and non-radioactive [115In_ 
DTPA-D-Phel]-octreotidel67. The binding of ["IIn-DTPA-D-Phel]-octreotide to rat brain 
18 
cortex membranes proved to be displaced similarly by natural SS as well as by octreotide, 
suggesting specific binding of [ll'In-DTPA-D-Phe'J-octreotide to SS-R's. 
Because of its longer half-life in the circulation, [ll' In-DTPA-D-Phe'J-octreotide is 
exposed longer to tumour tissue, which improves gamma camera imaging 24 hours after 
injection and its renal clearance without degradation in vivo contrasts to the hepato-biliary 
clearance of [I123-Tyi'J-octreotide and subsequent degradation in vivo. Therefore, ['llIn-
DTPA-D-Phe'J-octreotide is also very suitable for use in single photon emission computed 
tomography (SPECT) of the abdomen, which is especially of importance in the localization 
of small endocrine gastroenteropancreatic tumours, which are obscured by radioactivity from 
other organs, ego kidney and spleen l68.169. 
Figure V. 
[' ·[n-DTPA-D-Phe1j-ocrreoride. 
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CHAPTER II 
AIM OF THE STUDY 
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Somatostatin receptors (SS-R's) have been found on a variety of neuroendocrine 
tumours like carcinoids, paragangliomas and meningiomas. Several in vitro studies also 
indicated the presence of SS-R on part of human breast cancers, on islet cell tumours, but not 
on adenocarcinomas of the pancreas. This finding led us to explore whether it was possible 
to visualize SS-R positive breast and islet cell tumours in vivo. In order to validate that indeed 
SS-R expressing tumours were visualized, we investigated the correlation between the in vivo 
results and the presence of SS-R's as demonstrated in vitro by autoradiography of the same 
tumour specimen. 
The presence of SS-R's on part of human breast cancers raised two questions. First, it 
was investigated whether breast tumours expressing SS-R's form a distinct subgroup with 
particular genetic characteristics, and whether there is a correlation between SS-R expression 
and neuroendocrine differentiation of these tumours. For this reason we studied SS-R positive 
primary breast tumours for a number of clinical, genetic and pathological characteristics. 
Secondly, growth inhibitory effects of somatostatin had been previously demonstrated 
in experimental breast cancer tumour models. The mechanism(s) of this effect is currently 
poorly understood. It might be due to inhibition the synthesis of several auto- and paracrine 
growth factors, which act directly on the tumour cells or indirectly via tumour-derived 
fibroblasts which in previous studies were found to be capable of stimulating the growth of 
breast cancer cells. 
The culture of human breast cancer cells is difficult. It was decided to approach the 
problem of the preparation of primary cultures of breast cancer cells by incubating tumour 
associated fibroblasts and epithelial tumour cells separately. Thereafter the role of breast 
cancer derived fibroblasts was investigated on the proliferation of primary cultures of 
epithelial cells derived from the same tumour. Finally a potential inhibitory effect of the 
somatostatin analogue octreotide on tumour cell proliferation was studied. 
In contrast to most islet cell tumours, pancreatic duct cancers were previously found 
to be SS-R negative. As most islet cell tumours can be visualized with [lllIn-DTPA-D-Phe'J-
octreotide scintigraphy, it was investigated whether it is possible to differentiate 
preoperatively with this technique between these two tumour types and whether somatostatin 
receptor scintigraphy plays a role in the long term follow-up of these patients. 
Most patients with islet cell tumours eventually die because of extensive liver 
metastases. As liver metastases remain visible at scintigraphy of patients with islet cell 
tumours on the basis of the presence of SS-R's on the tumour cells, we further evaluated the 
pathophysiological significance of the SS-R's on these tumour cells. We performed a study 
in rats, bearing transplantable SS-R positive pancreatic and SS-R negative colon tumour cells, 
in order to investigate whether it was possible to inhibit the growth of SS-R positive liver 
metastases by octreotide administration, and whether an inhibitory effect of octreotide on the 
growth of liver metastases is specific for SS-R positive tumours. 
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SOMATOSTATIN RECEPTOR SCINTIGRAPHY IN PRIMARY 
BREAST CANCER 
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Abstract 
Somatostatin receptor scintigraphy successfully visualizes the primary tumonrs, as well 
as the distant metastases in most patients with carcinoids, islet cell turnoUTS and 
paragangliomas. Previous in vitro studies indicated that somatostatin receptors (SS-R's) are 
present on part of human breast cancers. In this study we report the scintigraphic visualization 
with ["lln-DTPA-D-Phe1j-octreotide of 39 of 52 primary breast cancers (75%) in 50 patients. 
Parallel in vitro autoradiography with [125I-Tyr'j-octreotide of 30 of these tumours showed a 
corresponding receptor status in 28 of them. A homogeneous, dense distribution of SS-R's 
detected in vitro resulted in a higher degree of accumulation of radioactivity at the tumour 
site in vivo. Non-homogeneous in vitro distribution of receptors pointed in most instances to 
the presence of a large non-invasive carcinoma component, mainly ductal carcinoma in situ 
(DCIS). Significantly more invasive ductal carcinomas could be visualized than invasive 
lobular carcinomas (85 vs 56%, resp., p < 0.05). Also the number of T, tumours which were 
visualized was higher than the TI tumours (86 vs 61 %, resp., p<0.05). Special detailed 
gamma camera images of the axillae visualized non-palpable tumour containing Iymphnodes 
in 4 of 13 patients with histologically proven micrometastases. 
In the follow-up after 2.5 years, SS-R scintigraphy in 28 of the 37 patients with an 
originally SS-R positive tumour, was positive in the 2 patients with clinically recognized 
metastases, as well as in 6 of the remaining 26 patients who were symptom-free at that 
moment. Ca 15-3 and CEA elevations were observed in only 2 and 1, respectively, of these 
patients during follow-up. 
Conclusions: A majority of primary breast cancers can be visualized by SS-R 
scintigraphy. Especially invasive ductal carcinomas are positive. In the follow-up after 2.5 
years 25% of the symptom-free patients who had Originally SS-R positive primary tumours, 
showed distant metastases at scintigraphy, without elevations of serum CA 15-3 and CEA 
levels in the majority of these patients. It is anticipated that this technique will be of value 
in selecting patients for clinical trials with somatostatin analogues andlor other medical 
therapy. Furthermore, octreotide scintigraphy is more sensitive than measurements of the 
usual serum tumour markers for detecting recurrences of SS-R positive breast cancer. 
Introduction 
Somatostatin receptors (SS-R's) have been found on a variety of neuroendocrine 
tumours like carcinoids, islet cell tumours, paragangliomas, as well as on brain tumours, like 
meningiomasl.'. A number of studies also indicate the presence of SS-R's on part of human 
primary breast cancers'" which are probably of neuroendocrine differentiated'. 
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Direct anti proliferative effect of somatostatin analogues have been reported on the 
growth of a variety of experimental tumours, including human breast cancer cell lines and 
explants, via a somatostatin specific receptor mechanisrn10- 11 • 
Recently we introduced a new nuclear medical technique in which SS-R positive 
tumours could be visualized in vivo, after the administration of a radionuclide labelled 
somatostatin analogue followed by gamma-camera scintigraphi'·16. In the present study we 
investigated the value of this technique in the visualization of the primary tumours and their 
axillary metastases of 50 breast cancer patients, as well as of the use of SS-R scintigraphy 
in the follow-up of these patients. Furthermore, its value to the detect recurrent disease was 
compared with the two serum markers CA 15-3 and CEA, which are most commonly used 
for this purpose in breast cancer. 
Methods 
Patients 
We studied 50 patients with 52 primary breast tumours (mean age 61 years [range, 38 
to 93]). After clinical examination and mammography, all 52 tumours were cytologically 
confirmed to be primary breast cancer. When the patients gave informed consent to 
participate in this study, bloodsamples were taken for measurements of tumour markers and 
SS-R scintigraphy was performed on an outpatient basis. After this scanning procedure all 
patients were operated within two weeks, except for one patient, who received chemotherapy 
due to a T, breast tumour. Only physical examination and chest X-ray were done 
preoperatively. None of the patients showed evidence of metastatic disease. There were no 
clinical signs for spread of the disease, either. 27 patients were treated by lumpectomy and 
axillary dissection, 22 with modified radical mastectomy (2 patients had a bilateral modified 
radical mastectomy). The Scarff, Bloom, and Richardson grade (SBR) was assessed by one 
and the same pathologist (R.v.P.) in all patients. The presence of SS-R's in 30 of these 
tumours was measured by in vitro autoradiography (J.C.R.) on cryostat sections of tumour 
tissue, as has been described previously in detail for other breast tumours1,'. 
Materinls 
The somatostatin analogue [DTPA-D-Phe1]-octreotide was obtained from Mallinckrodt 
Medical BV (Petten, The Netherlands). [DTPA-D-Phe1]-octreotide was labelled with "ultra-
pure" 111Indium. The labelling procedure has been described elsewhere1'. Doses ranged from 
200 MBq to 272 Mbq [111In-DTPA-D-Phe1]-octreotide. 
Scintigraphy 
Planar images were obtained with a large field-of-view gamma camera (Counterbalance 
3700, Siemens Gammasonics, Erlangen, Germany) equipped with a 190-KeV parallel-hole 
collimator. Generally, the field of view covered the chest and the very upper part of the 
abdomen. Starting 24 hours after injection of [111In-DTPA-D-Phe1]-octreotide planar chest 
images were obtained anteriorly and posteriorly, with additional images of the axillary region 
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with arms in elevated position. 500 Kcts were collected per image with a maximal counting 
time of 15 min. A simple high/moderate/low/negative system was used to define the 
accumulation of radioactivity by the tumours as visualized during the scanning procedure, 
carried out by E.P.K. and H.Y.O., who were not informed about the localization of the 
tumour. 
Tumour marker assays 
Serum samples were stored at -20"C before the assays were carried out. Serum CEA 
levels were determined by the enzyme immunoassay (ELISA) kits of Boehringer (normal 
upper limit normal concentration 10,0 ng/ml). Serum CA-15.3 was determined by ELISA kits 
of Centercor, Leiden, The Netherlands (normal upper normal concentration in serum 27 
Vlml). 
Results 
['ll In-DTPA-D-Phe'] -octreotide scintigraphy was carried out in 50 patients with 52 
primary breast tumours. 39 of these 52 tumours were visualized. The intensity of 
scintigraphic visualization varied considerably between tumours. In figure la the SS-R scan 
is shown of a 70 yr old lady with a bilateral tumour. Infigure Ib the corresponding receptor 
autoradiographic results obtained on sections of both tumours removed from this patient, 
show specific binding of ["'I-Tyr']-octreotide to these tumours. 
Figure I. 
a. rln-DTPA-D-Phe'j-ocrreoride scinrigraphy visualizing rhe bilateral breast tumours. 
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Figure I. 
h. Distribution of somatostatin receptors 
in both breast tumour samples of the 
same patient: 
(a) Haematoxylin-eosin stained sections 
containing mainly tumour tissue. 
(b) Autoradiogram showing total binding 
of ['251_ Tyr'j-octreotide. 
(c) Autoradiogram showing non-specific 
binding of [' 25I-Tyr'j-octreotide (in 
presence of 10.6 M Tyr'-octreotide). 
B 
c 
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In 30 of these 52 tumours autoradiographic studies of the surgically removed tumour 
tissue for the presence of SS-R could be done in parallel to the scintigraphy with ['lIIn-
DTPA-D-Phe'j-octreotide. SS-R's were present in 23 of these tumours. A comparison 
between the results of in vivo scintigraphy and in vilro aGtoradiography showed that receptors 
were found in both instances in 22 cases, while receptors were absent at both investigations 
in 6 cases. A discrepancy between the results obtained ;n vivo and in vitro was observed in 
2 cases. In one tumour a non-homogeneously sparse distribution of SS-R's was found at 
autoradiography, while the tumour was not visualized in vivo. In the other case we could see 
low radioactivity on the scintigram of the breast containing a SS-R negative tumour according 
to autoradiographic examination. Two types of SS-R distribution were recognized at 
autoradiography of these tumours: in 16 cases the receptors were homogeneously and often 
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densely distributed over the tumour tissue, while they were found to be non-homogeneously 
scattered throughout the tumour tissue in 7 tumours . The non-homogeneous SS-R distribution 
was in all cases mainly related to a large non-invasive ductal carcinoma component, which 
was not found in the other SS-R positive tumours. 
In retrospect especially those tumours showing a dense distribution of SS-R's in vitro 
had been visualized most clearly in vivo, whereas a low density in vivo coincides with a non-
homogeneous distribution of receptors. As an example figure lIa shows the scan of a 56 yr 
old patient with a T, ductal carcinoma with a large non-invasive component. In figure lib the 
in vitro autoradiographic study with ['25I-Tyr'j-octreotide shows only specific binding of 
somatostatin throughout the non-invasive component of this tumour tissue. The in vivo [L llln-
DTPA-D-Phe'j-octreotide scan in this patient showed non-homogeneous, low radioactivity 
(see for comparison fig.la and fig.lIa). 
Figure III shows the scintigram of a 39 yr old patient with a T, invasive ductal 
carcinoma of the left breast. Physical examination did not reveal palpable lymphnodes in the 
axilla. The scan made 24 hours after injection of the ['"In-DTPA-D-Phe'j-octreotide showed 
radioactivity in the axillary region, however. Indeed histological confirmation of axillary 
lymphnode metastases in the tissue removed at operation was made thereafter. 
Figure 11. 
a. fHln-DTPA-D-Phe'j-octreotide scintigraphy of a 56 yr old patient visualizing rhe tumour 
in the right breast weakly (arrow). 
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Figure ll. 
h. Distribution of somatostatin. receptors 
in a breast tumour sample of this 
patient: 
(a) HaemalOxylin-eosin stained sections 
contamIng non-invasive tumour 
tissue, ductal carcinoma in situ 
(DCIS). 
(b) Autoradiogram showing total binding 
of t 25]-Tyrj-octreotide. Only one 
limited region containing DC]S is 
strongly labelled. 
(c) Autoradiogram showing non-specific 
binding of F']-Tyrj-octreotide (in 
presence of ](J' M Tyr-octreotide). 
Out of the subsequent 13 consecutive patients with histologically proven non-palpable axiJ1ary 
Iymphnode micro-metastases and a positive SS-R scan of the primary tumour, these 
lymphnode metastases were visualized in 4 patients. None of the patients with a negative scan 
of the primary tumour showed abnormal radioactivity in the axillae or elsewhere in the body. 
Further analysis of patient data and the results of SS-R scintigraphy showed no 
correlation between ["'In-DTPA-D-Phe']-octreotide visualization of the tumours in vivo and 
age (table 1). Eighty five % of the ductal carcinomas could be visualized and 56% of the 
39 
lobular carcinomas (p<0.05; table 2). Also significantly more T, tumours were visualized 
than T, tumours (p<0.05;table 3). 
Figure 111. 
fUln -DTPA-D-Phe'j-ocrreOlide scinJigraphy of a 39 yr old patienr visualizing the breast 
tumour on the left side and also its axillary lymphnode metastases. 
Table 1. Probability of ftnding ("In-DTPA-D-Phe'j-octreoride uptake in primary breast 
tumours, relared to the age of the patienrs. 
Positive SS-R scan 
Age No. of tumours No. of tumours (%) 
< 60 yr. 18 15 (83%) 
> 60 yr. 34 24 (71%) 
The 37 patients with 39 SS-R positive primary breast cancers were selected to undergo 
repeat SS-R scintigraphy 2.5 years after initial therapy (after 23-36 months) . Of these patients 
2 had died (one due to metastatic breast cancer), 3 were bedridden at home in a bad clinical 
condition (2 related to metastatic breast cancer). Two patients had been discharged from 
follow-up because of their age and 2 patients refused to undergo repeat scintigraphy. 
Of the remaining 28 patients with an originally SS-R positive pri mary breast cancer 2 
patients had al ready undergone a repeat scintigraphy because of symptoms suspected for 
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metastases. In one of these patients SS-R positive metastases had been visualized in the liver, 
lung and cervical spine and in the other patient both axillary and mediastinal lymphnode 
metastases were seen on the side of the original breast tumour. 
Table 2. Probability of finding tIl In-DTPA-D-Phe'j-octreotide uptake in 
primary breast tumours, related to histology. 
Positive SS-R scan 
Histology No. of tumours No. of tumours (%) 
Ductal carcinoma 40 34 (85%) 
Lobular carcinoma 9 5 (56%)" 
Medullar carcinoma 2 0 
Tubular carcinoma 1 0 
Total 52 39 (75%) 
• p < 0.05 vs ductal carcinomas 
Table 3. Probabiliry offinding tIlln-DTPA-D-Phe'j-octreotide uptake of primary breast 
cancer, related to tumour size and pathological stage. 
Positive SS-R scan 
Tumour size No. of tumours No. of tumours (%) 
TI 23 14 (61%) 
T2 28 24 (86%)" 
T4 I I 
Pathological stage 
TjNo 15 9 (60%) 
T2NO 14 12 (86%) 
TINI 8 5 (62 %) 
T2NI 9 8 (89%) 
T2N2 5 4 (80%) 
T4N, I 1 
.p < 0.05 vs TI 
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The other 26 patients were symptom-free: both the clinical history, as well as physical 
examination were uneventful, while a yearly repeated mammogram was normal. In 6 of these 
26 patients [lI'ln-DTPA-D-Phe']-octreotide scintigraphy showed lesions suspected for 
metastases which could be confirmed by other diagnostic tools (biopsy, bone scan, ultrasound, 
CT-scan): bone (n=4), liver (n = 1) and pulmonary (n=2) as well as pleural (n= 1) metastases 
were readily seen, as well as metastases in axillary (n=2), infraclavicular (n=l) and 
mediastinal (n = 1) lymphnodes. In one patient, treated by lumpectomy and axillary dissection, 
a local recurrence was seen at SS-R scintigraphy. In figure IVa-c examples of the scans 
obtained in one patient are shown. 
a b c 
Figure IV. 
u. 58 yr old patient with primary breast cancer Qf the l~ft breast. Also the normal thyroid 
gland is visualized. (Histology: injiltratin[; ductal carcinoma, without axillary 
lymphnode metastases. 
h. 17 months later mediastinal and axillalY lymphnode metastases were visualized at 
somatostatin receptor scintigraphy on the left side. (Cytology: axillary lymphnode 
showed ductal carcinoma). 
c. Treatment with chemotherapy followed (6 cycles of Carboplatin 300 mg/m' and 
Etoposide 1oomg/m' intravenously every 4 weeks). Thirteen months later there was a 
complete disappearance Qf the axillary tumour uptake and a lower uptake of the 
mediastinal tumour. The axillary lymphnode metastases were not seen any more at the 
CT-examination, while the mediastinal tumour had the same size as b~fore. 
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Fourteen patients with an originally SS-R positive primary tumour which had been 
visualized, showed a normal somatostatin scan in the follow-up. Slight scattered radioactivity 
distributed over one lung was seen in 6 patients after radiotherapy which had been given after 
lumpectomy and axillary dissection. The 13 patients with an originally SS-R normal scan 
were not rescanned after 2.S years. None of these patients had died, all patients were 
symptom-free. 
Serum CA IS-3 and CEA levels were normal at first presentation in patients with SS-R 
positive primary tumours in 3S and 37 patients, respectively. None of these tumour markers 
was elevated in patients with primary SS-R negative tumours, of which the SS-R status is 
based on SS-R scintigraphy. At follow-up only one of the symptomatic patients had elevated 
CA IS-3 and CEA levels, and also only one of the asymptomatic patients had an increased 
level of CA IS-3, which however was already elevated on admission. 
All patients with a normal SS-R scan in their follow-up had serum tumour marker levels 
in the normal range except for one patient who had a slightly elevated CA IS-3 as was the 
case at first presentation (table 4). 
Table 4. CA 15-3 and CEA levels in parients with SS-R positive primary breast tumours and 
proven recurrent disease according to SS-R scintigraphy atfollow up of 30 months. 
Patient 
category CA IS-3(U1ml) CEA (ng/ml) 
Symptomatic Admission Follow-up Admission Follow-up 
(n=2) 17 23 2 2 
17 331 I 30 
Asymptomatic 
(n=6) II 14 I I 
42 92 I 2 
II 11 I I 
22 20 I I 
22 22 8 8 
2S 21 2 2 
Symptomatic: Patients with clinically overt metastatic disease 
Asymptomatic: Patients without clinically overt metastatic disease 
Normal value: CEA < 10 ng/ml; CA-IS-3 < 27 Dlml 
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Table 5. CA 15-3 and CEA mean levels in 29 patients with SS-R positive primary breast 
tumours and in 20 patients with normal SS-R scintigraphy at follow-up of 30 
months. 
Nine patients had no follow-up. 
Tumour marker Admission Follow-up 
CA 15-3 (U/ml)' 18 (7-38') 17 (6-40') 
CEA (ng/ml)' 3 (1-6) 3 (1-8) 
, mean levels 
• values of the same patient 
Table 6. CA 15-3 and CEA levels at .first presentation in 13 patients with SS-R negative 
primary breast tumours. 
Tumour marker Mean Serum value (range) 
CA 15-3 (U/ml) 15 (6-22) 
CEA (ng/ml) 2 (1-5) 
Discussion 
The SS-R imaging technique has been shown to be successful in the visualization of the 
primary as well as metastatic tumour sites of a variety of neuroendocrine tumours like 
carcinoids, islet cell tumours and paragangliornas12.1(i, Validation of this technique was 
reached by the in vitro demonstration of high-affinity binding sites for somatostatin on those 
tumours, which had been visualized in vivo", In parallel a positive SS-R scan closely 
predicted a beneficial effect of chronic octreotide therapy on hormonal hypersecretion by 
these tumours. 
Also part of human breast cancers contain SS-R's as measured, In a group of 158 
"small" breast cancer samples with a mean section surface of 14 mm2 34 tumours (21 %) were 
SS-R positive, while in a group of 72 "larger" tumour samples with a mean section surface 
of 180 mm2 33 tumours (46%) were SS-R positive', A subpopulation of SS-R containing 
breast tumours is probably neuroendocrine differentiated, as shown by Papotti et al 8 , Studies 
by Bussolati et al.17 and Papotti et al 8 indicated a high variability of the incidence of 
neuroendocrine characteristics in breast cancer. The percentage of positive cases varied. not 
only according to the specificity and sensitivity of the neuroendocrine markers used, but 
depended also on the number of tissue slices per tumour investigated microscopically", 
In the present study we visualized 39 of 52 primary breast cancers (75 %) with SS-R, 
There was a close correlation between the in vivo ['"In-DTPA-D-Phe'j-octreotide scan and 
subsequent in vitro findings at autoradiography with 123I-Tyr'-octreotide, also confirming and 
validating the concept of receptor imaging in this kind of tumour. There was considerable 
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variability in the accumulation of radioactivity at SS-R scintigraphy. A higher density in vivo 
turned out to correlate in most instances with a homogeneous and dense distribution of SS-R's 
throughout the tumour at autoradiography, while a lower density of radioactivity over the 
tumour area in vivo in most instances corresponded with a non-homogeneous and often sparse 
distribution of these receptors. Interestingly, the low density of receptors in vivo and in vitro 
seemed to be due to the occurrence of a non-invasive carcinoma component, mainly being 
ductal carcinoma in situ. 
The high incidence of SS-R's in these 52 carcinomas (as observed with the in vivo 
technique) might be related to several causes: firstly, it is hypothesized that in vivo SS-R 
visualization of the primary breast cancer is more sensitive than in vitro autoradiography 
using sections of parts of the turnOUT only, as this nuclear medical technique investigates in 
fact the presence of receptors three-dimensionally in the entire tumour. In accordance with 
this, statistically significantly more T2 tumours than TJ tumours were visualized in vivo. 
Secondly, our patients might represent a "selected" group in comparison with those found in 
other countries, as the incidence of ductal carcinomas amongst the patients with newly 
diagnosed breast cancers has increased over the last years in the Netherlands after the 
introduction of routine and especially repeated screening of the population!9. Significantly 
more (locally) invasive ductal carcinomas were visualized with this technique. 
Very little is known concerning the biological behaviour of SS-R positive breast cancer 
in man. In a retrospective study involving 11 0 patients Foekens et al. 20 suggested that the 
presence of SS-R might predict a longer disease-free survival. Also in vitro studies in more 
than 300 breast cancer samples showed an inverse relationship between somatostatin and 
EGF-receptor expression"'. These observations suggest that patients with SS-R positive 
cancers might have a relatively good prognosis. This, however, seems not to be substantiated 
by our observations. In the follow-up after 2.5 years we found that from the 37 patients with 
a SS-R positive tumour at least 5 had extensive metastases (one had died, two were bed-
ridden because of metastases and in two symptomatic patients the scan indicated the presence 
of multiple metastases), while also 6 of 26 symptom-free patients had (multiple) histologically 
proven metastases, as initially visualized at SS-R scintigraphy. It is unclear at present how 
much time might have elapsed before the disease would have become symptomatic in these 
cases. 
CA 15-3 and CEA are the most commonly used tumour markers to monitor patients 
with recurrent breast cancer. Both markers are elevated in only 5-20% of women with 
primary breast cancer, but elevations between 61 and 84% have been recorded for women 
with extensive metastatic disease. CA 15-3 seems to be related to the extent of the metastases, 
the number of metastatic sites and survival, whereas CEA is only correlated with the extent 
of disease21 ,22. 
In this study we show a higher sensitivity of SS-R scintigraphy compared with these 
tumour markers to detect the development of recurrent breast cancer in patients with SS-R 
positive primary breast cancer. SS-R scintigraphy demonstrated recurrent disseminated breast 
cancer in 8 (only two of whom were symptomatic for recurrence) out of 28 patients with 
SS-R positive primary tumours. Six patients had normal CA 15-3 and CEA serum values 
(table 4-0. Another three out of these 28 patients had abnormal serum tumour markers, two 
of whom had an abnormal SS-R scintigram. The third patient, who only showed marginally 
elevated CA 15-3 serum levels both at first presentation and follow up, is clinically without 
evidence of disease 3.2 years after operation. Possibly the CA 15-3 in this patient is false 
positive for breast cancer. 
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Our data include a number of new aspects with regard to the diagnosis and therapy of 
breast cancer. We have presented evidence that the technique of peptide receptor visualization 
of primary breast cancer with a radionuclide-Iabelled somatostatin analogue is successful in 
75% of cases. At the primary diagnosis the scintigraphic technique seems of minor value in 
the detection of axillary lymphnode metastases. Very often axillary lymphnode metastases 
include only microscopically recognized tumour cell nests. 
The results sofar also suggest that the (distant) metastases of the primary somatostatin 
receptor breast tumours continue to express such receptors at 2.5 years after the initial 
therapy. The scintigraphic technique showed the unexpected presence of (multiple) metastases 
in nearly 25% of symptom-free initially SS-R positive breast cancer patients, who had normal 
CA 15-3 and CEA serum values. At the moment one can only speculate what the clinical 
relevance is to detect recurrent disease in an early stage. 
Studies with breast cancer cell lines indicate a direct receptor-mediated inhibitory effect 
of somatostatin (analogues) on cell proliferation1o.".". No prospective, controlled studies on 
the use of somatostatin analogues in patients with breast cancer have been published yet. It 
is concluded, that the technique of SS-R is effective in the early detection of SS-R positive 
breast cancer recurrence. Therefore it may be used in the future for the selection of patients 
who can be treated with somatostatin analogues and/or other forms of therapy. Also 
radiotherapy with an ,,- or 6-emitting radionuclide coupled to a somatostatin analogue might 
be considered, especially when disseminated disease is recognized. 
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Abstract 
In a series of 87 primary breast tumours, somatostatin receptor (SS-R) expression was 
detected by in vitro autoradiography in 58 tumours. In 41 tumours the SS-R expression was 
homogeneous and in 17 it was heterogeneous. Although the tumours were not selected by the 
investigators upon entry in the study, examination of the tumour and patient characteristics 
showed that a pre-selection had taken place for small tumours. Eighty percent of the tumours 
were classified as stage pTl or pT2 tumours. The large size of the tumour sections used for 
autoradiography can explain the high incidence of somatostatin expression in our series. 
Forty-three of these tumours, 30 SS-R positive and 13 SS-R negative, were tested for 
morphological and (immuno)histochemical markers ofneuro-endocrine differentiation. Three 
SS-R positive tumours were also positive for 2 or more other markers of neuroendocrine 
differentiation, suggesting that neuroendocrine breast tumours and SS-R positive breast 
tumours are overlapping, but independent, subgroups of tumours. To test whether specific 
genetic alterations are associated with SS-R positive or SS-R negative breast tumours, we 
examined in a selected series of 47 SS-R positive and 32 SS-R negative breast tumours a 
number of known genetic markers by Southern blotting. Deletions or rearrangements of the 
retinoblastoma (RB) tumour-suppressor gene were observed in 5 SS-R positive and 5 SS-R 
negative tumours. In 4 SS-R positive and also in 4 SS-R negative tumours an amplification 
of the neu oncogene was observed. Amplifications of the inl-2 oncogene were found in 2 
SS-R positive and 1 SS-R negative breast tumour. In one SS-R positive tumour an 
amplification of the c-myc oncogene was observed and in another SS-R positive tumour a 
rearrangement of the L-myc oncogene was found. These results indicate that no correlation 
exists between SS-R expression and alterations of the RB gene or amplifications of one of the 
investigated proto-oncogenes. 
Introduction 
The study of breast carcinogenesis is complicated by the heterogeneity of the disease. 
One way of simplifying the matter is to subdivide these tumours into clinically relevant 
subgroups. There are indications that breast carcinomas which express the somatostatin 
receptor (SS-R) are such a distinct subset. For example, patients with a SS-R positive tumour 
have a better prognosis'. Tumours of these patients show a correlation between SS-R and 
oestrogen receptor expression and an inverse correlation between SS-R expression and 
epidermal growth factor (EGF) receptor expression'·). Papotti and co-workers reported a 
correlation between SS-R expression and neuroendocrine differentiation in a series of 100 
primary breast tumours4 . 
Alterations in oncogenes and tumour-suppressor genes are the fundamental changes that 
can lead to tumour formation. In breast cancer a number of genetic changes have been 
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identified:loss of heterozygosity of the chromosome regions lq, 3p, lip, 13q14 (RB gene), 
17p13, 18q and amplifications of the int-2, myc and neu oncogenes'-'- At present it is not 
clear whether these genetic alterations are equally important in all types of breast cancer or 
whether a particular combination of events is present in a histologically and clinically distinct 
subgroup of tumourslO,n, The finding of neu amplifications predominantly in the comedo type 
ductal carcinoma in situ' and loss of heterozygosity of regions of chromosome 22q in lobular 
carcinoma' strongly support this latter possibility, 
The aim of this study was to investigate whether breast tumours expressing SS-R are 
a distinct subgroup at the genetic leveL To this end a series of primary breast tumours was 
collected and tested for SS-R expression and genetic alterations, We chose genetic markers 
that are frequently altered in both breast carcinomas and in neural or endocrine tumours such 
as neuroblastoma and small cell lung carcinoma, These are alterations of the retinoblastoma 
gene (RB) andlor amplification of members of the myc family of oncogenes. Amplification 
of the neu and int-2 oncogenes were also studied since these frequently occur in breast 
cancer. 
Furthermore, clinical and pathological characteristics of the tumours were investigated, 
In addition, to test whether the reported correlation between SS-R expression and 
neuroendocrine differentiation was present in this population, 43 tumours were also examined 
for neuroendocrine differentiation characteristics. 
Material and methods 
Patient material 
Eighty seven breast tumours were obtained from the surgical departments of the 
Dijkzigt Academic Hospital and the Dr. Daniel den Hoed Cancer Centre in Rotterdam 
between 1984 and 1990. Immediately after removal of the tumour, one part was taken for 
histological examination and the remainder was snap frozen and stored in liquid nitrogen until 
use. Genetic studies were begun on 27 tumours from our archives, that were selected for 
presence or absence of the SS-R. All tumours were histologically classified according to the 
criteria of Azzopardi et aL "-
Patient and tumour characteristics were compared with SS-R status of the tumours, Data 
were collected on age at onset, oestrogen receptor status, lymphnode involvement, histology, 
stage and differentiation grade of the tumours, These data are summarized in table 1. 
Somatostatin receptor autoradiography 
Frozen tumour samples were shipped on dry ice to the Sandoz Research Institute in 
Bern (Switzerland), where the SS-R's were measured by autoradiography on 10 I'm cryostat 
sections. The size of the sections was over 100 mm'. As a ligand, the iodinated stable 
analogue of somatostatin [1251_ Tyr'j-octreotide was used. Incubation and washing conditions 
were as described'. Non-specific binding was determined by adding unlabelled [Tyr'j-
octreotide. Results were scored on a semi-quantitative scale. A tumour was counted as 
positive when specific binding was at least twice as high as the non-specific binding obtained 
by incubation in the presence of non-radiolabelled octreotide. Positive ·results were further 
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classified as homogeneously positive when the whole section of tumour tissue stained positive. 
A tumour was heterogeneously positive when patches of positive cells were present in the 
tumour section. 
Table 1. Clinical and pathological data from 87 primary breast tumours. 
SS·R poo. 
", SS·R neg. T<)~l Ik>mogenrou. Heterogeneou. 
Number "'. 
" 
~ 
" " 
",. 57.5 ~ 56.2 56.9 ~ .• 
,"' 45164(76%) 14121(67%) 31/43(72%) 20128(71 %) 11115(73%) 
Nod .. ' 31m{4:2%) 12126(46%) 19/47(40%) 14f3J(4<I%) 5114{36%) 
Slag.' ,n 30181(37%) 8"/29(::8%) 21152(40%) 17137(46%) 41ISPS%) 
,n 38181(46%) 16129(55%) 2215::l(42%j t5f37(40%) 7115(47%) 
,TI 6181(7%) lr.l9{3%) 5151(10%) 3137(8%) 2115(13%) 
,H 81111(10%) 41:9(14%) 415::l(8%) 2137(5%) 1117{?%) 
G",d.' 15184(18%) 41:9(14%) 11/55(20%) 6m!(U%) 5/17(19%) 
n 27/84{32%) 81:!9(Z8%) 19I5S(4S%) B/3S(34%) 6/17(35%) 
m 41J84(50%) 17W(!?%) 25155(45%) 19138(50%) 6117(35%) 
'M""" "tl." In y""r •. '> Illfmollmg cylffiol proleln, m",,-,urod h~' 111l"nd hlndlng a.""y or enzyme Immun",,".""~'.'P"'I ... urgl<21 reglon~l lymph nod .. pr .. cnl.'pT I""'Hurgl<21 
primary lumour ''''l;e accordIng 10 TNM d~ •. '\f1c;ollon. 'I, highly dIITer."l\alod;ll. mode""lely dllT ... nll~lod;lII, poorly dIIT ... nUalod.'For .peclflc .ubgroup" lh. numbor do 
IIO[ add up to 87 duo 10 ml ... lng ""Iu ... 
Histology and immunohistochemistry 
Sections of 5 I'm were cut from formalin-fixed, paraffin-embedded tumour tissue. For 
histological examination the sections were stained with either haematoxylin and azophloxin 
or haematoxylin and eosin. To examine the neuroendocrine differentiation the original 
Grimelius silver impregnation method was usedB , Other neuroendocrine differentiation 
markers were examined using serial sections collected on poly-L-Iysine treated slides and 
processed for immunohistochemistry. Antibodies against neuron-specific enolase (NSE) 
(DAKO, Copenhagen, Denmark), chromogranin A (ENZO, New York, NY, USA) and 
chromogranin B (Dr. H. Winkler, [nnsbruck, Austria) were used as described". 
Southern hybridizalions 
Between 5 and 10 p.g of DNA, isolated from frozen tumour samples and peripheral 
blood lymphocytes (as control), were digested with HindIII restriction enzyme, separated by 
electrophoresis on 0.8% agarose gels, and transferred to Hybond N+ nylon membranes 
(Amersham, Aylesbury, UK). The membranes were hybridized to 32p-oligolabelled DNA 
probes. Hybridization and washing procedures were performed under standard conditions. 
After autoradiography on XAR films (Eastman Kodak, Rochester, NY, USA) for I to 7 days 
the membranes were stripped using 0.5% NaDodSo, (lOOoC, 15') and re-hybridized. 
Hybridization to a myoglobin (MB) DNA probe served as an internal control for the amount 
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of DNA in each lane and the level of amplification. The following probes were used: RE, a 
0.9 and a 3.8-kb EcoRlcDNA fragment; int-2, a 1.0-kb BomHI-Kpnl BK4 fragment; c-myc, 
a 1.6-kb Clal-EcoRI fragment; L-myc, a 1.8-kb Smal-EcoRI fragment; N-myc, a 1.0-kb 
EcoRI-BamHI fragment; neu, a 1.6-kb cDNA fragment and myoglobin, a 0.6-kb Bglll-
EcoRI pcr-made fragment. 
Results 
Somatostatin receptor expression 
Somatostatin receptor expression was assessed by autoradiography using a radiolabelled 
somatostatin analogue, [Tyr'l-octreotide. In our series of 87 consecutive tumours, SS-R 
expression was detected in 58 tumours (67%). In 41 of these, (47%) SS-R expression was 
homogeneous and in 17 (20 %) heterogeneous receptor expression was observed. The 
remaining 29 tumours (33%) showed no detectable SS-R expression. An example of an 
autoradiogram showing heterogeneous receptor expression is given in figure I. 
Figure /, Heterogeneous expression of 
somatostatin receptors. 
(a) H&E stain of a seerion of a primary 
breast carcinoma, showinJ? tumour 
tissue throughout the section 
(b) Autoradiogram showing toral binding 
of the radiolabel/ed somatostatin 
analogue /"I-Tyr'j-octreotide to a 
serial sect;on of the same tumour 
(c) Autoradiogram of the same tumour 
after incubation of labelled ['251_ Tyr'j-
octreotide in the presence of 1(J6M of 
unlabelled [Tyr'j-octreotide, showing 
non-specific bindinK 
Bar:lmm 
A 
B 
c 
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Neuroendocrine differentiation 
Neuroendocrine differentiation was tested in 43 samples from 52 non-selected tumours 
used in the genetic studies, from which paraffin embedded tumour tissue was available. The 
tumours were reviewed for neuroendocrine differentiation characteristics such as solid growth, 
lack of exocrine differentiation and monotonous cell morphology. In addition sections were 
stained by the Grimelius procedure and consecutive sections were incubated with antisera 
against neuroendocrine differentiation markers neuron specific enolase (NSE) and 
chromogranin A and B. The results are listed in table 2. 
Table 2. Neuroendocrine markers in primary breast tumour}. 
Case Histology2 NSE Chrom.A Chrom.B Grimelius SS-R 
1 + 
3 + + 
6 + + 
15 5% + 
18 5% 3% ++ 
20 + ++ 
22 + ++ 
23 3% 
25 + + 
26 + + 
27 + + 
28 ++ ?3 ++ 
31 5% 
37 + 
39 + ++ 
43 + 20% + 
45 + + ?J + 
49 + ++ 
50 + ++ 
51 + + 
'Only those tumours that were positive for one or more markers are listed. 
2Presence of histological characteristics of neuroendocrine differentiation: 
solid growth, lack of exocrine differentiation and monotonous cell morphology. 
'Non-specific result. 
NSE positivity was detected in 17 samples. In 4 tumour samples 3, 3, 5 and 20% of 
the tumour cells, respectively stained positive with the Grimelius procedure. In one of the 
tumours positivity for chromogranin A was detected in 5% of the cells. In another tumour 
5 % of the tumour cells were positive for chromogranin B. 
We arbitrary scored a tumour as having a neuroendocrine differentiation when it was 
positive for at least 2 of these markers. Three tumours met this criterium: case 45 showed 
neuroendocrine morphological characteristics and was NSE positive, but negative for all other 
neuroendocrine markers;case 18 showed Grimelius and chromogranin A positivity in 3 and 
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5% of the cells, respectively;case 43 was NSE and Grimelius positive in 50 and 20% of the 
cells. These three tumours also expressed the SS-R and are regarded as having a weak neuro-
endocrine differentiation. 
Genetic alterations 
Genetic alterations of the RB gene and amplification or alteration of the neu, inl-2, c-
myc, L-myc and N-myc oncogenes were investigated on Southern blots in 79 primary breast 
tumours. Thirty six tumours expressed the SS-R homogeneously, 11 expressed the receptor 
heterogeneously and in 32 tumours no SS-R's could be detected. The tumours were not 
otherwise stratified. The results are shown in table 3. 
Deletion or rearrangement of the RB gene was detected in 10 tumours, of which 3 
showed homogeneous SS-R expression, 2 heterogeneous SS-R expression and 5 were SS-R 
negative. Neu amplifications were detected in 4 SS-R positive and 4 SS-R negative tumours. 
In 2 SS-R positive and one SS-R negative sample, int-2 amplification was observed. One of 
these samples showed co-amplification of the neu and int-2 oncogenes, and one had both a 
deleted RB gene and inl-2 amplification. C-myc amplification was observed in 1 SS-R positive 
tumour. Rearrangement of the L-myc oncogene was detected in 1 SS-R positive tumour. No 
alterations of the N-myc gene were detected. Compared to the hybridization signal of the 
myoglobin gene, 5 to 15 fold amplifications were observed. 
Table 3. Genelic alleralions in 79 primary breasllumours in relalion 10 SS-R expression. 
SS-R expression 
Gene alteration Homogeneous Heterogeneous Negative 
RB Yes 3(8%) 2(18 %) 5(16%) 
No 33 9 27 
Neu Yes 4(11 %) 0 4(12 %) 
No 32 11 28 
inl-2 Yes 2(5%) 0 1(3%) 
No 34 II 31 
c-mycl Yes 1(3%) 1(12%) 0 
No 29 7 30 
L-myc' Yes 1(3 %)3 0 0 
No 30 10 30 
N-myc Yes 0 0 0 
No 36 11 32 
168 tumours were tested for c-myc amplification and 271 tumours 
for L-myc alterations-3rearrangements 
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Figure II. RB alterarions in breast tumours. 
kb 
- 9.8 
75 
6.2 
5A 
4.5 
- 3.2 
- 2.1 
Autoradiogram (If a Southern biOI containing HindllI-digested DNA from 8 different 
primary breast tumours in lanes 1 to 8 and from lymphocyte control DNA in lane N. 
The blot was hybridized to a 3.8 kb-RBI eDNA probe. 
Examples of such rearrangements and amplifications on Southern blot are shown in 
figure IIand III. In figure II lanes 1-8 contain HindlII digested tumour DNA's and lane N 
HindlII- digested control DNA from normal peripheral lymphocytes. This Southern blot was 
hybridized to a 3' RB eDNA probe. Two tumour DNA's show a clear rearrangement of the 
RB gene. The tumour in lane 5 shows an extra equimolar 3.2-kb fragment, and in lane 3 the 
top 2 hybridizing fragments of 9.8 and 7.8-kti are less intense then the other hybridizing 
fragments in this tumour, indicating a partial deletion of the RB gene. Figure III shows 
HindlII-digested tumour DNA's, hybridized with probes for the neu and c-myc oncogenes. 
The hybridization pattern of the myoglobin gene (MB) is included as a control for the amount 
of DNA. A neu-amplification is visible in lane d, where compared to the MB signal, the neu-
signal is 5 times stronger. 
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Figure III. Oncogene ampificarion in breasr rumours 
kb 
- 9.5 
- 8.0 
- 11 
Autoradiogram qf a Sourhern blor conraining Hindl/l-digesred DNA from 5 differenr 
primary breasr rumours, afrer hybridizarion ro neu and c-myc gene probes. The DNA's 
were also hybridized lVirh a myof!,lohin f!,ene probe (MB) as a conrrolfor rhe amounr of 
DNA. 
Discussion 
In our series of 87 primary breast tumours, we detected SS-R expression in 67% of the 
tumours. The incidence of SS-R expression was much higher than that reported in the 
literature to date. However, concurrently with this study, we screened a partly overlapping 
group of 50 patients for SS-R expression using an in vivo SS-R scanning technique prior to 
operation. In this group of patients, 75 % of the tumours were positive for SS-R expression 
(Chap.III). Other studies on SS-R expression in breast cancer report an incidence of 10 to 
47% .. Fekete et a1." detected binding of somatostatin in 36% of 500 breast cancer biopsy 
homogenates. Using autoradiography Reubi and Torhorst' and Papotti et a1. 4 detected specific 
somatostatin analogue binding in 17%-20% of primary breast tumours. However, in a more 
recent study Reubi et a1. 3 detected somatostatin analogue binding in 46% of primary breast 
tumours. In that study much larger tumour sections (l80±8 mm') were examined for SS-R 
expression than previously. Over 50% of the SS-R positive tumours showed heterogeneous 
SS-R expression, which had not been detected previously and which may explain the 2-fold 
difference in incidence upon comparison with earlier studies. 
In the present study we also used large tumour sections (> 100 mm2) for 
autoradiography. However, in this series only 17 of the 58 SS-R positive tumours showed 
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heterogeneous SS-R expression. Thus, a lower detection limit as a result of the use of larger 
tissue sections and subsequent detection of more heterogeneous SS-R positive tumours cannot 
fully explain the high incidence of SS-R positive tumours in this series of breast tumours. 
Compared with other reports14 our tumour series showed a similar distribution of age 
at onset and oestrogen receptor expression. Moreover, no difference was observed between 
the SS-R positive and SS-R negative tumours. However, our tumour population contained a 
high percentage of Tl/T2 stage tumours (83 %). This high percentage was found in both the 
SS-R positive and the SS-R negative subgroups, but the frequency of Tl tumours was higher 
in the SS-R positive group. In only one other study on SS-R expression, has tumour size been 
reported1'. In that report Tl and T2 stages made up 59% (16/27) of the tumours and 3127 of 
these tumours were SS-R positive. 
A trend towards smaller tumour size in the Dutch breast tumour population was also 
observed in a larger study by Coebergh et a1 n , who reported a 2-fold rise in incidence of 
pTl tumours (28 to 42%) and a 50% reduction ofpT3/pT4 tumours in the years 1970-1986. 
The authors suggested that this shift towards smaller tumours could be due to the earlier 
detection as a result of population screening programs. Another factor contributing to the low 
percentage of later-stage tumours in our series, was the policy of the Surgery Department of 
the Dijkzigt Academic Hospital not to operate on patients with a clinically assessed T4 
tumour. These T4 tumours were therefore seldom available for study. This bias in our set 
of tumours should be born in mind when comparing the results of the present study with those 
of other studies. 
( 
Therefore, a possible explanation for the high incidence of SS-R expression reported 
in this study could be the combination of a high percentage of pTl/pT2 tumours and the large 
size of the tumour sections (not of the tumours themselves) used for SS-R autoradiography, 
which allowed the detection of heterogeneous receptor expression. 
Small tumour size has been correlated to a favourable prognosis and recently also to a 
lower differentiation grade (i.e. better tumour differentiation)l'. Our data show a tendency 
towards a lower differentiation grade in SS-R positive tumours. This is concordant with 
clinical data assigning a favourable prognosis to patients with SS-R positive tumours. 
Since SS-R expression has been correlated to neuroendocrine differentiation in other 
tumour type', such as lung cancer, we tested 43 tumours for expression of other markers of 
neuroendocrine differentiation. Seven percent (3/43) of these tumours showed neuroendocrine 
differentiation, which is within the range of 5-10% reported by others"1'. Since we found a 
normal low frequency of neuroendocrine differentiation, but a high incidence of SS-R 
expression in the same series, we conclude that SS-R receptor expressing breast tumours and 
those showing neuroendocrine differentiation in this study are overlapping, but independent 
subgroups. 
In a selected group of 79 tumours we investigated whether any of the genetic alterations 
that are frequently observed in breast tumours were specific for the SS-R positive or SS-R 
negative subgroups. The Southern-blot method, used to detect changes in the RB gene and 
the neu, int-2 and myc oncogenes, does not permit identification of all possible alterations in 
these genes, but is useful for detecting subgroup specificity of these alterations. Our results 
indicate that no significant correlations exist between the presence or absence of the SS-R and 
the loss of the RB tumour-suppressor gene. Similarly, none of the investigated oncogene 
amplifications or rearrangements are specific for the subgroup of the SS-R positive or SS-R 
negative breast tumours. The RB and myc genes were chosen because they were reported to 
be altered in both breast cancer and neuroendocrine tumours. Our observations that these 
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alterations also occur in SS-R negative tumours lacking neuroendocrine markers suggests that 
these genetic changes are not restricted to breast tumours with neuroendocrine differentiation. 
Nesland et al. 19.20 reported that neu amplification and neuroendocrine differentiation are 
mutually exclusive in breast tumours. In our series we detected 3 breast tumours with weak 
neuroendocrine differentiation. None of these tumours contained an amplified neu oncogene. 
This observation is in line with that of Nesland et al. 20, although the numbers are small. 
No other reports have been published on the relation between genetic alterations and 
expression of the SS-R in breast tumours. Some data are, however available on the 
relationship between amplification of the neu oncogene and expression of the EGF receptor. 
A correlation between neu over-expression and EGF receptor expression was reported by 
Marx et al. 21 • This observation was in contrast to the results of others who did not find such 
a correlation22.23 • In the present study SS-R content of the tumours was assessed. However, 
we have reported earlier that SS-R and EGF receptor expression are mutually exclusive in 
breast cancer'. This implies that the observed lack of correlation between SS-R expression 
and neu amplification and EGF receptor expression, accord with each other. 
It is worth while to test other genetic markers in the subgroup of SS-R positive breast 
tumours, because the SS-R expressing breast tumours are a clinically relevant subgroup, and 
also because a high percentage of early stage tumours in this subgroup gives an opportunity 
to study those genetic alterations that are involved in the initial steps of tumour formation. 
Addendum 
First of all the high incidence of the SS-R expression found in this study, using 
autoradiography in large tumour sections, correlates well with the numbers of tumours which 
could be visualized in vivo by the [lllIn-DTPA-D-Phel]-octreotide scintigraphy (Chapter III). 
Although the data found in this study showed a tendency towards better differentiation of 
SS-R breast tumours, this by no means is an indication towards better prognosis. Out of the 
37 patients with a SS-R positive tumour 5 patients were found to have, clinically overt, 
recurrent disease during 2.5 years of follow-up, which is in contrast with the 17 patients with 
an initially SS-R negative tumour, who were all without evidence of-disease (Chapter III). 
Several retrospective studies suggested that the presence of SS-R might predict a longer 
disease free survival,. however in these studies small breast samples were investigated and 
therefore low numbers of SS-R positive tumours were found. In order to define the biological 
behaviour of SS-R positive breast cancer in man, prospective studies have to be carried out 
with a much longer follow-up period, using the somatostatin receptor scintigraphy for 
identification of SS-R positive tumours, since this nuclear medical technique investigates the 
presence of the receptors in the entire tumour, and may directly stage the patient Therefore 
this ~n vivo visualization technique is preffered to in vitro detection of SS-R's by for instance 
autoradiography. 
In the 11 patients with recurrent SS-R positive. disease no specific alterations or 
amplifications of the investigated genes could be found and only 2 of the tumours from these 
patients showed neuroendocrine differentiation. 
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CHAPTER V 
ROLE OF TUMOUR-DERIVED FIBROBLASTS IN THE GROWTH OF PRIMARY 
CULTURES OF ffiJMAN BREAST CANCER CELLS: EFFECTS OF EPIDERMAL 
GROWTH FACTOR AND THE SOMATOSTATIN ANALOGUE OCTREOTIDE 
Int J Cancer in press 
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Summary 
In the present study we have investigated in a co-culture system using Transwell tissue 
culture inserts with microporous membranes, the role of human breast cancer-derived 
fibroblasts in the proliferation of primary cultures of epithelial cells derived from the same 
tumour. Fibroblasts and epithelial cells were enriched according to differences in their density 
on Percoll density gradients. The co-culture system was first established using MCF-7 breast 
cancer cells and a human fibroblast line (HF cells). 
Insulin (10 fLg/ml), 17il-oestradiol (E2; 10 nM), Epidermal Growth Factor (EGF; 10 
ng/ml), and HF cells all significantly stimulated growth of MCF-7 breast cancer cells. The 
stimulatory effects by insulin, E2, and EGF were additive to the stimulatory effect by HF 
cells. These data suggest that (unique) factors, other than the above mentioned growth 
promoting compounds, are responsible for the growth promoting effects by fibroblasts. 
In 3 out of 6 human breast cancers investigated tumour-derived fibroblasts stimulated 
tumour-derived epithelial cell proliferation. EGF (10 ng/ml) significantly stimulated epithelial 
cell proliferation in 4 out of 6 cultures. The stimulatory effects of fibroblasts and EGF were 
additive or synergistic, and were observed in the additional presence of fetal calf serum, again 
suggesting production of unique factors by the fibroblasts. In one culture the fibroblasts 
significantly inhibited epithelial tumour cell proliferation. In reverse, the epithelial cells 
significantly stimulated proliferation of fibroblasts in 3 out of 3 cultures. The somatostatin 
analogue octreotide (I Nm) significantly inhibited epithelial cell proliferation by 46% in one 
tumour cell culture in the absence, but not in the presence of fibroblasts. Interestingly, in one 
culture octreotide significantly inhibited the proliferation of fibroblasts co-cultured with 
epithelial cells. 
In conclusion, our study clearly emphasizes the need to investigate in breast cancer the 
role of stromal cells on epithelial cell proliferation, as well as their role in interfering with 
drug-induced manipulation of breast cancer cell growth. 
Introduction 
Culturing primary human breast cancer cells has prove to be difficult. The most 
successful method appears to be treatment of the tissue with collagenase, subsequent I x g 
sedimentation of epithelial clumps and culturing the cells in media with specific substitutesl .'. 
One of the problems underlying these difficulties in culturing human breast cancer cells may 
be the dependency of the individual cancer cells for an intact autocrine and paracrine growth 
regulatory apparatus which is proposed to exist in vivo"'. Recent laboratory studies also point 
to an important role of stromal cells in the development and growth of breast cancer. 
Conditioned media from human breast cancer-derived fibroblasts have been shown to enhance 
the growth of several human breast cancer cell lines via the secretion of (unknown) growth 
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factors"'. This stimulatory effect of stromal cells on the growth of malignant breast epithelial 
cells has also been demonstrated in vivo"'. 
The importance of stromal-epithelial interactions in the growth of epithelial tumour cells 
led us to investigate the growth of primary cultures of human breast cancer cells in the 
absence and presence of the corresponding tumour-derived fibroblasts. For this, we first 
separated the epithelial cells and fibroblasts on discontinuous Percoll density gradients. This 
method of enrichment of breast cancer cell populations has been applied successfully before". 
Thereafter we have co-cultured both cell populations using Transwell tissue culture inserts 
with microporous membranes. In addition we also studied the effects of EGF and the 
somatostatin analogue octreotide in this co-culture system. A non-homogeneous distribution 
of receptors for EGF and somatostatin has been demonstrated by autoradiography by Reubi 
et al. 1I in 46% of large tumour samples of human breast cancer tissues, while in the same 
study 25 % of the somatostatin receptor (SS-R) positive breast tumours were shown to contain 
EGF receptors. These two receptor types were not topographically overlapping in the majority 
of the cases, however. The growth factor and the neuropeptide may be involved in positive 
and negative growth regulation of human breast cancer cells, respectively. More knowledge 
about the interrelationship between the direct and indirect effects of octreotide and EGF on 
the growth of human breast cancer cells is of clinical importance in the light of recent clinical 
trials in which patients with advanced breast cancer are treated with octreotide12 • The co-
culture system using Transwell tissue culture inserts was first established using MCF-7 human 
breast cancer cells and human fibroblasts (HF) cells. 
Materials and methods 
Cell dispersion and separation of cells according to differences in their density. 
Fresh tissue from 6 malignant breast tumours was obtained within 30 minutes after 
surgical removement. Histological diagnosis of tumour tissue was confirmed by routine histo-
pathological examination. All specimens were diagnosed as infiltrating ductal carcinomas. The 
tissue was minced into pieces of approximately 1 mm3, washed twice with isolation medium 
(see below), centrifuged at 100 x g for 5 min., and incubated overnight in culture medium 
containing 2 giL collagenase. Thereafter, the remaining cell pellet was washed twice with 
isolation medium and incubated for another 1 hour at 37'C with a mixture of collagenase and 
dispase (1 giL and 2.4 x 10' UIL, respectively) in order to obtain a single cell suspension. 
After this incubation period the cells were washed twice with isolation medium. The 
remaining cell suspension consisted of single cells now. An aliquot of this suspension was 
separated, the cells were counted and plated in multi well plates (see below) and represents 
the original cell suspension. The remaining cells were layered on a discontinuous Percoll 
density gradient (1.04-1.05-1.06-1.07-1.08-1.10 glml) and centrifuged to isodensity during 
20 min. at 800 x g. The cells present in the different fractions (interphases) were collected, 
washed twice with isolation medium, counted and cultured as described below. Percoll was 
obtained from Pharmacia (Uppsala, Sweden). 
Cell culture 
The human epithelial tumour cells with equilibrium densities of > 1.07 glmPO, were 
resuspended in culture medium, counted and seeded in multiwell plates in a concentration of 
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25.000 cells per well. Fibroblasts with an equilibrium density of < 1.05 glmllO were 
resuspended in culture medium, counted and seeded in a number of 25.000 cells per 
Transwell in Transwell microporous membranes (0.4 I'm; Costar Europe Ltd., Badhoevedorp, 
The Netherlands). The Transwells were transferred into wells containing I ml of culture 
medium without or with epithelial cells. Thereafter, the epithelial cells (wjthout or with 
fibroblasts) were incubated without or with test-substances for 5-7 days. During the last 24 
hours 3.7 x 10' Bq of [methyl-3H]-thymidine was added to the wells. The medium was 
removed, the cells were washed twice with ice-cold 0.15 moliL NaCl, solubilized with I 
moliL NaOH and transferred to vials for scintillation counting of the incorporated 
radioactivity. 
The isolation medium was Hanks' Balanced Salt Solution (HBSS) supplemented with 
10 giL human serum albumin, penicillin (lO' UlL) and sodium bicarbonate (0.4 giL). Culture 
medium consisted of DMEM/F-12 (l:l) supplemented with non-essential amino acids, fetal 
calf serum (10%), human transferrin (l0 I'g/L; Sigma), ascorbic acid (50 I'M) and sodium 
selenite (6 I'g/L). Media and supplements were obtained from Gibco Brl (Paisley, Scotland). 
Human transferrin and ascorbic acid were obtained from Sigma Chemical Company (St. 
Louis, MO, USA), sodium selenite from Merck (Darmstadt, Germany). 
MCF-7 human breast cancer cells were kindly provided by Dr. C. Quirin-Stricker 
(Institute de Chimie Biologique, Faculto de MOdecine, Strasbourg, France). Fibroblasts 
isolated from human foreskins (HF cells) were kindly provided by Dr. M. Ponec (Academic 
Hospital Leiden, Leiden. The Netherlands). MCF-7 and HF cells were cultured in culture 
medium and were passaged twice a week using trypsin (0.05%) and EDTA (0.02%). In the 
experimental incubations, the MCF-7 cells (25.000 cells seeded per well) were cultured in 
multi well plates in I ml culture medium with or without HF cells (2 x 10' cells per 
Transwell). After I day of culture, the medium was replaced by serum-free culture medium. 
After another I day of incubation, this medium was replaced by medium containing 10% 
growth factor inactivated fetal calf serum and the cells were incubated for 2 days without or 
with test-substances. Under these conditions optimal stimulation of MCF-7 cell proliferation 
by mitogens such as insulin or insulin-like growth factors is found!'. At the end of the 
incubation the DNA content of the cells was measured using the bisbenzimide fluorescent dye 
(Behring Diagnostics, La Jolla, USA) as described previously!4. Insulin (bovine) was 
purchased from Sigma, epidermal growth factor from Bissendorf Biochemicals (Hannover, 
Germany). 
Immunocytochemical detection of keratin and BrdU 
For keratin- and BrdU- staining the epithelial cells were cultured on glass coverslips. 
For keratin-staining, the cells were fixed at the end of the incubation period during 10 min. 
with methanol. Staining for keratin was done using a DAKO PAP KITTM System (code K518; 
DAKO AIS, Glostrup, Denmark). For BrdU- staining, the cells were incubated for 60 min. 
with 5-bromo-2'-deoxy-uridine, washed twice with PBS, and fixed during 20 min. at -20°C 
in 70% ethanol in glycin buffer (50 mmollL, pH 2.0). Staining for BrdU was done using a 
BrdU- labelling and detection Kit II from Boehringer (cat. no. 1299 964; Boehringer 
Mannheim B. V., Almere, The Netherlands). The cells were double-stained for keratin using 
the DAKO PAP KITTM System as described above. 
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Statistical analysis of data 
All values are expressed as mean ± SE, n=3 wells per treatment group. All data were 
analyzed using analysis of variance (ANOV A) to determine overall differences between 
treatment groups. When significant overall effects were found by ANOV A, a comparison 
between treatment groups was made using the Newman-Keuls test". P < 0.05 was considered 
to be statistically significant. 
Results 
Fibroblast-epithelial cell interactions in cell lines 
We first established the co-culture system using transwell tissue culture inserts in MCF-
7 human breast cancer cells co-cultured with human fibroblasts (HF cells). In initial 
experiments we determined the number of HF cells that were required to significantly 
stimulate MCF-7 cell proliferation. Figure 1 shows that a low number of HF cells (10.000-
20.000 HF cells seeded per transwell) only slightly stimulated MCF-cell proliferation, while 
a higher number (200.000 cells) stimulated MCF-7 cell proliferation by 76%. In the further 
co-culture studies we therefore used this higher number of HF cells. 
Figure 1. 
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The effect of human fibroblasts (HF cells) on the growth of MCF-7 breast cancer cells. 
HF and MCF-7 cells were co-cultured during 4 days using Transwell tissue culture 
inserts with microporous membranes as described in the Materials and Methods section. 
Open bars: MCF-7 cells without HF cells, filled bars: MCF-7 cells with HF cells; 
·p<O.Ol and ··p<O.05 vs MCF-7 cells without HF cells. 
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In figure II the effects of 17/3-oestradiol (E2) and insulin on MCF-7 cell growth with 
or without co-culture with HF cells is shown. The HF cells significantly stimulated 
proliferation of MCF-7 cells (+61 %; p < 0.01 vs cells without HF cells). E2 (10 nM) and 
insulin (10 I'g/ml) alone significantly stimulated MCF-7 cell proliferation by 76 and 75 %, 
respectively (p < 0.01 vs control cells). The effects of E2 and insulin were ~dditive and not 
synergistic to the stimulatory effect of the HF cells on MCF-7 cell proliferation. EGF (10 
ng/ml) had, under these conditions, only a marginally stimulating effect (+25%, P < 0.01 vs 
control cells). Again, the effect of EGF was additive to the effect of HF cells on MCF-7 cell 
growth (data not shown). 
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Figure 11. The effect of insulin (INS) and I7/3-oestradiol (E2) on MCF-7 cell growth, with 
(filled bars) or without (open bars) co-culture with human fibroblasts (HF cells). 
MCF-7 and HF cells were co-cultured during 4 days as described in the 
Materials and Methods section. Insulin (10 I'glml) and E2 (10 Nm) were added 
on day 3 of culture. ·p<O.OI vs control; +p<O.OI vs cells without HF cells. 
Stainingfor keratin and incorporation of BrdU in primary cultures o/human breast cancer 
cells. 
In initial experiments, we have cultured cells from all fractions of the Percoll density 
gradients. On the basis of haematoxylin stained preparations of these fractions we found that 
cells with densities of less then 1.05 glml had a fibroblast-like appearance, while cells with 
a density of more then 1.07 glml were clearly epithelial-like. The intermediate density 
fractions showed a mixture of both cell types. In the further studies we therefore used cells 
with densities of < 1.05 glml (enriched in fibroblasts) and> 1.07 glml (enriched in epithelial 
cells) only. The original, un separated cultured cell suspension consisted of both cell types, 
with a preponderance of fibroblasts. We also observed in most cultures that the Percoll-
enriched fraction of epithelial cells grew best in the presence of fibroblasts and EGF (10 
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ng/ml) . Photomicrograph lA shows an example of the staining for keratin of an epi thel ial 
cell population co-cultured with fibroblasts and EGF (10 ng/ml). Virtually no fibroblasts 
(keratin-negative) are present. Photomicrograph IB shows absence of staining using non-
immune rabbit serum instead of rabbit antiserum to human keratin proteins . 
Photomicrographs lC and ID show an example of a double-staining for keratin and 
BrdU in proliferating cells from the same tumour. Photomicrograph 1 C shows that in the 
original, un separated cell suspension both proliferating fibroblasts (blue nucleus, keratin-
negative) and epithelial cells (blue nucleus, keratin- positive) are present. In contrast, 
photomicrograph ID shows that in the enriched epithelial fractio" , mainly proliferating 
epithelial cells are present. 
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Photomicrograph 1: 
Photomicrograph of immunocytochemical staining for keratin and/or BrdU of human 
primary breast cancer cells co-cultured with stromal cells derived from the same 
tumours. A:breast cancer-derived Percoll-enriched epithelial cells co-cultured with 
fibroblasts and EGF (10 ng/ml), keratin staining (red-brown); B:cells as in A, 
negative control (normal rabbit serum) keratin staining; C:originai cell suspension 
from breast cancer specimen as in A, cultured in the presence ofEGF, double-staining 
for keratin (red-brown) and BrdU (blue nuclei); D:epithelial enriched cells, co-
cultured with fibroblasts and EGF as in A, double-staining for keratin and BrdU. 
Magnification bar = 50 I'ill. 
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Therefore, measurement of 3H-thymidine incorporation in the enriched epithelial cell 
fraction will indeed represent proliferation of epithelial cells, and we performed further 
studies on the effects of fibroblasts on the proliferation of enriched epithelial breast cancer 
cells. Using this co-culture system also the effects of EGF (10 ng/ml) and the somatostatin 
analogue octreotide (1 Nm) were studied. 
The effect of tumour -derived fibroblasts on 3H-thymidine incorporaJion in tumour-derived 
epithelial cells. 
Figure III shows the effect of Percoll-enriched fibroblasts (F) on 3H-thymidine 
incorporation of Percoll-enriched tumour-derived epithelial cells of six breast cancers. The 
fibroblast fraction significantly stimulated 'H-thymidine incorporation in 3 out of 6 cultures 
(no. 1, 2 and 5), and inhibited 'H-thymidine incorporation in one (no. 3). 
tumor , tumor , tumor , 
I I • I 
. -; 
~1 r -
.' , ~~ , • I ~ ~ 
'! , ~ • • 
"" '" 
, Ecr+r 
"" '" 
, EGF+r 
"" '" 
, lep.y 
tumor 4 lumo,5 tumor 6 
1 2000 •• 
'"'I 
5000 J , ,~ 
' ' 
.! 4000 
j 1200 ~ 
·'w J 3000 ~ ... , . . , , 1 '"0 , , ~ ~ • '"' , '! 
• • 0 • 
'" '" 
, ~GF+F 
"" '" 
, EOF+F 
'" 
." 
, EGF+r 
Figure III. The effecrs of breast cancer- derived fibroblasts (F) and 10 ng/ml epidermal 
growth faclOr (EGF) on 3H-thymidine incorporation by Percoll-enriched 
epithelial cells derived from the same tumours. Fibroblasts and epithelial cells 
were co-cultured using Transwell tissue culture inserrs as described in the 
Materials and Methods section. ·p<O.Ol and "p<O.05 vs control; +p<O.01 
vs EGF alone. CON=control, EGF= 10 ng/ml EGF, F=fibroblasts. 
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EGF (10 ng/ml) alone significantly stimulated 3H-thymidine incorporation in 4 out of 6 
cultures (no. 3, 4, 5, 6). The effects of fibroblasts and EGF were significantly synergistic in 
2 cultures (no. I and 4), and additive in one culture (no. 5). In contrast, in the culture of 
tumour no. 3 the fibroblast fraction significantly inhibited EGF-stimulated 3H-thymidine 
incorporation. 
In two cultures from histologically proven non-malignant tissues (one blunt duct 
adenosis and one chronic granulomatous inflammation) we found that the fibroblast fraction 
inhibited epithelial cell growth, while in one the fibroblast fraction completely blocked EGF-
induced stimulation of epithelial cell proliferation (data not shown). 
The somatostatin analogue octreotide (I Nm) had no statistically significant effect on 
epithelial cell proliferation either in the absence or in the presence of fibroblasts in tumour 
no. I, 2, 4, 5 and 6, whereas in tumour nO.3 octreotide significantly inhibited epithelial cell 
proliferation by 46% (p < 0.01 vs control) only in the absence of fibroblasts (data not shown). 
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The effect of Percoll-enriched epithelial breast cancer cells on the growth of 
fibroblasts derived from the same tumours. Both cell types were co-cultured 
using Transwelltissue culture inserts as described in the Materials and Methods 
section. - = without epithelial cells, + = with epithelial cells; ·p<O.OI vs 
fibroblasts without epithelial cells. 
In three cultures (tumour no. 2, 5 and 6) we also studied 3H-thymidine incorporation 
in fibroblasts cultured in the absence and in the presence of epithelial cells. In addition to the 
stimulatory effect of tumour-derived fibroblasts on epithelial cell proliferation, we found that 
the Percoll-enriched epithelial cells also significantly stimulated fibroblast proliferation. This 
is shown in figure IV. In the presence of epithelial cells, EGF (10 ng/ml) significantly 
stimulated fibroblast proliferation in all cultures (table 1). In fibroblasts, co-cultured with 
epithelial cells, octreotide significantly inhibited 3H-thymidine incorporation in lout of 6 
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cultures (no.5). There were not sufficient stromal cells obtained after Percoll-gradient 
separation in order to also study the effects of EOF and octreotide on the growth of 
fibroblasts that were not co-cultured with tumour-derived epithelial cells. 
Table 1. The effects o/EGF and octreotide on 3H-thymidine incorporation o/fibroblasts co-
cultured with primary breast cancer cells. 
3H-thymidine incorporation (cpm per dish) 
Tumour no. Controls EOF (IOng/ml) Octreotide 
(InM) 
I 428± 110 1450± 153' 685±279 
2 457±70 1417±86' 349±23 
3 29±2 58±5' 33±3 
4 77±11 177±7' 56±5 
5 90±7 126±6' 58± I' 
6 114±19 235±20' 138±31 
'p < 0.01 vs control;values are mean ± SE, control = fibroblasts co-cultured with 
primary breast cancer cells. 
Discussion 
Previous studies have demonstrated that human breast cancer-derived stromal cells 
secrete factors capable of stimulating the proliferation of breast cancer tumour cell lines"'. 
While mammary tumour epithelial cell growth is regulated by steroid hormones and 
polypeptide growth factors3 .• ,!" the nature of stromal factors responsible for stimulation of 
epithelial cell growth is still unclear. In the present study we investigated in a co-culture 
system using transwell microporous membrane inserts, the role of human breast cancer-
derived fibroblasts in the growth regulation of epithelial cells derived from the same 
corresponding tumours. This co-culture system was first established using MCF-7 breast 
cancer cells co-cultured with a human fibroblast line (HF cells). In line with other studies"',!' 
we found that fibroblasts are capable of stimulating the proliferation of MCF-7 breast cancer 
cells. _ 
Most studies on stromal-epithelial interactions in human breast cancer have been 
performed using conditioned media from breast cancer-derived stromal cells capable of 
stimulating human breast cancer cell line proliferation"'. In the present study we provide 
preliminary evidence for the existence of such a paracrine-growth stimulatory mechanism in 
a co-culture system of primary human breast cancer cells and stromal cells derived from the 
same tumours, although there was a considerable variability among the tumours. In 50% of 
the human tumour cell cultures we found that tumour-derived stromal cells stimulated the 
proliferation of epithelial cells derived from the same tumour. In one culture, however, the 
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stromal cells even inhibited epithelial cell proliferation. In two tumour cell cultures we 
showed that fibroblasts and EGF acted synergistically on epithelial cell proliferation, while 
in three other cultures the EGF-stimulatory effect was only slightly additive and not 
synergistic to the fibroblast-stimulated epithelial cell proliferation. Finally, in one culture the 
tumour-derived fibroblasts even significantly inhibited EGF-stimulated epithelial cell 
proliferation. In two cultures from "non-malignant" breast tissue-derived fibroblasts and 
epithelial cells we also observed an inhibitory effect of fibroblasts on epithelial cell 
proliferation. These data are partly in agreement with the results of a recent study by 
Roozendaal et aI. 7 , who suggested a higher stimulatory response of breast cancer cell lines 
to conditioned media of breast cancer-derived fibroblasts as compared to that of normal breast 
tissue derived-fibroblasts. They suggested that this was most likely determined by the 
phenotypic characteristics of the fibroblast cells involved, which may be different between 
normal tissue and tumour-derived fibroblasts. Moreover, Adams et a1. 6 also found that normal 
tissue-derived fibroblast conditioned medium had an inhibitory effect on MCF-7 cell 
proliferation, while conditioned medium from tumour- derived fibroblasts was strongly 
stimulatory. Other investigators have shown either stimulatoryS,7,R,17 or inhibitory 18 effects of 
normal tissue- derived fibroblasts on epithelial cell proliferation. In the same co-culture 
system which we used in the human primary tumour cell cultures we found that normal 
human foreskin-fibroblasts were only stimulatory on human MCF-7 cell proliferation. It 
seems very important therefore, to study stromal-epithelial interactions on cells derived from 
the same tissue specimen. 
Interestingly, we found that the tumour-epithelial cells also had a stimulatory effect on 
fibroblast proliferation. This suggests that within human breast cancer an autocrine growth 
regulatory route exists in which fibroblasts stimulate epithelial cells and epithelial cells 
stimulate fibroblasts. Breast cancer cells have been shown to secrete many growth factors (i.e. 
tumour growth factor (TGF)-a, TGF-~ and platelet derived growth factor (PDGF», while 
also fibroblasts are capable of secreting growth factors4 , particularly insulin-like growth 
factors (IGFs)19. In the present study we did not investigate the nature of the epithelial cell 
and fibroblast-derived factors responsible for the observed autocrine growth stimulation. 
However, the results of our study indicate that fibroblasts and growth factors (i.e. insulin, 
EGF and E2) act additive or synergistically on the proliferation of malignant breast cancer 
cells. In addition, in the human primary cell cultures we found that fibroblasts have a 
stimulatory effect on breast cancer cells, even when both cell types are grown in the presence 
of EGF and serum. This suggests that factors, other than the above growth promoting 
compounds, are responsible for the growth promoting effects induced by fibroblasts. The 
observed opposite effects of "non malignant breast tissue"- and" breast tumour tissue"-
derived fibroblasts on epithelial cell proliferation suggest that the ratio's of growth stimulatory 
and growth inhibitory factors secreted may be different between "normal" and "tumour" 
fibroblasts, since it is unlikely that fibroblasts produce one specific growth factor only. 
In approximately 50% of human breast cancer specimens receptors for somatostatin 
have been demonstrated, while EGF receptors were found in 25 % of the samples containing 
somatostatin receptors (SS-R's). In only 8% of these cases the two receptor types were 
topographically overlapping". On the basis of these data Reubi et aI." suggested that in the 
majority of breast tumours it is unlikely that tumour biology is influenced by a direct 
interaction of somatostatin and EGF through specific receptors in a particular cell. In a wide 
variety of experimental tumour models, including breast cancer, growth inhibitory effects by 
long-acting somatostatin analogues have been demonstrated in vivo and in. virro20,2J The in vivo 
tumour-growth inhibitory effects by somatostatin analogues may act indirectly via the 
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inhibition of angiogenesis, immune modulatory effects, and via the inhibition of the secretion 
"endocrine" growth factors as growth hormone, prolactin and IGF-I, as well as via direct 
effects on tumour cells via specific SS-R's. These latter effects include inhibition of EGF-
receptor activity via the stimulation of a tyrosine-phosphatase or inhibition of the secretion 
of autocrine and paracrine growth factors21 . Because we found clear evidence in our study for 
the existence of a paracrine growth regulatory mechanism, we also studied the effect of the 
somatostatin analogue octreotide on epithelial cell and fibroblast proliferation with or without 
co-culture. We found that octreotide had no effect on basal and fibroblast-stimulated epithelial 
cell proliferation in 5 of 6 tumours, while in one tumour octreotide inhibited epithelial cell 
proliferation in the absence of fibroblasts only. Surprisingly, we found in one culture that 
octreotide significantly inhibited the proliferation of fibroblasts co-cultured with epithelial 
cells. Although we did not investigate the SS-R status of the tumours, it can be speculated 
that octreotide inhibits the secretion of growth factors by the epithelial tumour cells, thereby 
indirectly inhibiting growth of the co-cultured fibroblasts. In the 7-day co-culture period 
which we used in our study, this growth inhibitory action by octreotide on fibroblast 
proliferation did not result in an indirect growth inhibition of epithelial cells. Therefore, more 
studies are needed to evaluate a possible role of the somatostatin analogue octreotide in the 
treatment of breast cancer. 
In conclusion, our study emphasizes the need to investigate in breast cancer the role of 
stromal cells on epithelial cell proliferation, as well as their role in interfering with drug-
induced manipulation of breast cancer cell growth. 
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CHAPTER VI 
USE OF RADIONUCLIDE-LABELLED SOMATOSTATIN ANALOGUES FOR 
VISUALIZATION OF ISLET CELL TUMOURS 
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Abstract 
The results of visualization of the islet cell tumours of 25 patients after intravenous 
administration of two isotope-labened somatostatin analogues ([1231_ Tyr'j-octreotide and [111In-
DTPA-D-Phe!j-octreotide) are described. The primary tumours, as well as previously 
unrecognized distant metastases were visualized in 20 of the 25 patients (80%). Parallel in 
vitro detection of somatostatin receptors (SS-R's) on those tumours that had also been 
visualized in vivo indicates that the ligand binding to the tumour in vivo indeed represents 
binding to specific SS-R's. It is an easy, quick, harmless procedure that is available for 
localization of primary endocrine pancreatic tumours and their often radiologically and 
clinically not yet recognized metastases. 
Introduction 
SS-R's have been shown to remain present on a variety of tumours which arise in 
tissues also containing these receptors in the normal state. High numbers of high affinity 
SS-R's have been found on most growth hormone secreting pituitary adenomas as well as on 
most metastatic islet cell tumours and carcinoids!·). In parallel chronic therapy with octreotide 
normalizes clinical symptomatology as well as the biochemical abnormalities in most 
acromegalic patients: both the hyper-secretion of growth hormone, and the elevated 
circulating levels of insulin-like growth factor I (virtually) normalize in most instances'. 
Hormonal hypersecretion from (metastatic) endocrine pancreatic tumours and carcinoids is 
also well controlled during octreotide treatment in most patients, while in parallel clinical 
symptomatology greatly improves. Interestingly, evidence for control of tumour growth 
during somatostatin analogue treatment has been observed in part of these patients'. These 
results led to an instant improvement in the quality of life of these patients, making the 
clinical introduction of octreotide a major breakthrough in the treatment of these endocrine 
cancers. 
It was remarkable to us that in the in vitro autoradiographic studies of most of these 
endocrine tumours (pancreatic and carcinoids) was virtually always a very high density of 
SS-R's was present within these tumours in contrast to the virtual absence of visible binding 
sites in the surrounding "normal" tissue which was known also to contain these receptors 
(jig. la-c). The presence of higher numbers and/or a higher affinity of the SS-R's on many 
of these tumours seemed also to be reflected by the clinical observation that tumorous 
hormone secretion (i.e. in acromegalic and/or gastrinoma patients) was much longer 
suppressed after the single subcutaneous administration of octreotide than normal growth 
hormone and/or gastrin secretion in healthy individuals6• 
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Figure T. 
Somatostatin receptors in a case 
of a human gaslrinoma 
(a) HaemalOxylin-eosin srained 
section. 
(b) AUlOradiogram showing loral 
binding of 1251_ Tyr' -octreolide. 
(c) AUlOradiogram showing non-
specific binding in the presence 
of 1 ".g Tyr'-octreoride. 
Bar = 1 mm. 
c 
These considerations led us to explore, whether it might be possible to detect SS-R 
positive tumours in vivo after the administration of a radioactive iodine labelled analogue7 • 
In a way one might call this approach an " in vivo autoradiography" of SS-R positive 
tumours. 
Material and Methods 
Tyr'-octreotide is a somatostatin analogue with tyrosine in posltlOn 3, where 
phenylalanine is present at that place in octreotide. The biological activities of octreotide and 
Tyr'-octreotide are similar. We coupled Tyr' -octreotide to 1231 and injected about 555 MBq 
[123I-Tyr']-octreotide intravenously in patients which were suspected to have SS-R positive 
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tumours, while planar or SPECT (single photon emission computed tomographic) images 
were made with a gamma camera. 
After the bolus injection of radioiodinated Tyr'-octreotide rapid accumulation of 
radioactivity was seen in the liver. About 50 percent of the activity was cleared from the 
blood pool within 2 minutes after injection and the localization of a variety of tumours and 
their metastases was possible. 
After the initial success of the visualization with [123I-Tyr']-octreotide of the primary 
tumours as well as the metastases of a variety of SS-R positive tumours, we were concerned 
about several drawbacks to this technique: the cyclotron-produced radionuclide 1231 is not 
readily available in many parts of the world. Its short half-life of about 12 hours hampers its 
use. while we found that very high-quality specifications of the isotope are required in order 
to ensure its successful use in scintigraphy. 1231 is also very expensive. Another problem, 
especially in the visualization of islet cell tumours and abdominal carcinoids is that [123I-Tyr']-
octreotide is excreted via the liver, gall bladder and bile ducts into the gastro-intestinal tract, 
making these parts of the body so "hot" with radioactivity that small primary tumours in this 
region can easily be missed, especially if no SPECT (single photon emission computed 
tomography) pictures are made. 
In order to circumvent these drawbacks we designed an alternative peptide: DTPA-
octreotide (DTPA=diethy1enetriaminopenta-acetic acid), which can be very easily conjugated 
with 111In. el1In-DTPA-D-Phe1]-octreotide has a much longer half-life (of about 3 days), and 
it is excreted via the kidneys'. Our experience in over 250 patients with different tumours 
indicates that [111In-DTPA-D-Phe1]-octreotide even better visualizes SS-R positive tumours 
than [1231_ Tyr']-octreotide. Physiological organ accumulation of [111In-DTPA_D_Phe1]_ 
octreotide is seen in the kidneys, spleen, liver, bladder, and the thyroid and pituitary glands. 
Results and Discussion 
The [123I-Tyr']-octreotide scanning procedure revealed the localization of the primary 
tumour andlor its previously unknown metastases in 7 of 9 patients with islet cell tumours. 
In 5 of the 7 positive tumours we could subsequently investigate the surgically removed 
tumour'. There was a close relationship between the in vilro detection of SS-R's in these 
tumours using autoradiography and the gamma camera pictures obtained after injection of 
[ 123I-Tyr']-octreotide. This indicates that the ligand binding to the tumour in vivo represents 
binding to specific SS-R's. In addition we carried out preoperative in vivo hormonal studies 
and in vitro experiments with cultured tumour cells. Again there was a close parallel between 
the presence of SS-R's on these tumours and the in vivo and in vilro effects of octreotide on 
hormonal secretion by these tumours. This means that a positive scan predicts a beneficial 
effect of therapy with octreotide on hormonal hypersecretion by these tumours. Furthers 
arguments in favour of the conclusion that indeed membrane receptors for somatostatin were 
visualized with this scintigraphic technique are that in vivo competition was observed between 
radio1abelled octreotide with regard to binding to SS-R positive tumours lO 
In table 1 we compared the results of in vilro autoradiography of a group of 35 islet cell 
tumours with the results of in vivo scintigraphy in 25 patients with these tumours. SS-R 
imaging in these patients was carried out initially in the first nine of these patients with e23I-
Tyr']-octreotide, and in the rest of them with ["1In-DTPA-D-Phe1]-octreotide. 
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Table 1. Incidence of somatostatin receptors on endocrine pancreatic tumours in vitro (as 
demonstrated by autoradiography) and in vivo (as demonstrated by scintigraphy. 
Incidence of somatostatin 
analogue receptors 
in vitro in vivo 
VIPomas 7/8 (87%) III 
Gastrinomas 515 (100%) 10111 (91 %) 
Glucagonomas 3/3 (100%) 1/1 
Insulinomas 8111 (72%) 5/8 (63%) 
GRF-omas 4/4 (100%) -
"non-functioning" islet cell 4/4 (100%) 2/2 
tumours 
Somatostatinomas 1/2 
Eight of these tumours have been investigated both in vitro 
and in. vivo. In all cases the results in vitro and in vivo investi-
gations were parallel. 
The application of SS-R imaging turned out to be highly successful. The primary 
endocrine pancreatic tumours as well as their often previously not yet recognized metastases 
could be visualized in 20 of these 25 patients (80%). Metastases were actually 
scintigraphically evident in II patients. Ten of these patients were subsequently operated upon 
in our hospital, allowing surgical evaluation of the scintigraphic results. In one gastrinoma 
patient no Iymphnode metastases on the aortic arch was not found at operation. despite the 
fact it was suggested at CT scanning. In another gastrinoma patient, who had familial multiple 
endocrine adenomatosis type I, the scintigraphically detected tumour was indeed found in the 
tail of the pancreas, but during operation an additional islet cell tumour was found in the 
corpus of the pancreas. This tumour had not been seen on the scan. Unfortunately no 
somatostatin autoradiography of this tumour was done. Examples of the gamma pictures 
obtained in two patients are shown in figure II and Ill. 
81 
Figure II. 
rllIln-DTPA-D-Phe1j-octreotide scan qf a 34 yr old patient with a metastatic 
somatostarinoma. Gama camera picture from the posterior view qfter 24 hours shows 
multiple bone metastases in the vertehrae and ribs, as weil as a Iymphnode metastases 
on the left part in the neck. 
Figure lII. 
tllln-DTPA-D-Phe1j-octreotide scans of a 1,5 em insulinoma in the head of the 
pancreas. 
(a) Anterior view qf the abdomen obtained at 24 hours. 
(b) Anterior view of the abdomen obtained at 48 hours. 
Both planar imalies demonstrate a hot spot just medial to the right kidney. Note the 
different distribution qf the radioactivity in the intestine visualized on the 1W0 images. 
The visualization of insulinomas with this technique turned out to be more difficult. We 
localized the tumours on the scan in only 5 of 8 patients investigated sofar. In vitro 
autoradiography showed that all in suI om as contained receptors for somatostatin-14 and -28, 
but that octreotide receptors were absent on the tumours, which could not be visualized in 
vivo. 
In conclusion, islet cell tumours are (in most instances) malignant tumours originating 
from endocrine cells pancreatic islet cells. The primary tumours, as well as the spread of the 
disease are often difficult to localize with current radiological techniques". Somatostatin 
receptor scintigraphy is an easy, painless non-invasive new diagnostic technique in patients 
with this type of tumours, which in our hands considerably helps in localizing the primary 
tumours, as well as their metastases. Prospective controlled studies comparing this procedure 
with other currently used investigative techniques should further delineate its sensitivity and 
specificity. 
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Abstract 
Somatostatin receptors (SS-R's) are present on most islet cell tumours, while previous 
in vitro studies indicate the absence of these receptors on pancreatic duct cancers. 
Somatostatin receptor scintigraphy (SRS) has become a technique which has shown to localize 
the primary as well as metastatic spread of islet cell tumours with a high sensitivity. 
In the present study the potential value of SRS was evaluated in the preoperative 
differential diagnosis of pancreatic duct cancer, as well as in the follow-up of these patients. 
In none of the 26 patients suspected of pancreatic duct cancer SRS was positive. In 
correspondence also all 16 tumour samples obtained from these patients, which could be 
investigated with in vitro autoradiography did not have SS-R's. 
Out of 62 patients with pancreatic duct cancer, who had been operated upon between 
1985 and 1990, 12 patients were alive for more than 3 years. Five of these 12 patients were 
known to have metastases. SRS was negative in 7 patients who were considered to be cured, 
while SRS was positive in 5 patients who had metastatic disease. In most of them SRS also 
visualized additional previously unknown tumour sites. Revision of the tissue samples with 
specific neuroendocrine staining techniques demonstrated that all 5 patients had "oon-
functioning" islet cell tumours. 
This study suggests that SRS might be of use in the preoperative differential diagnosis 
between islet cell tumours and pancreatic cancer, as well as in the follow-up, especially in 
those cases in which the pathological examination of the tumour tissue had not included 
special staining techniques for neuroendocrine characteristics. 
Introduction 
Preoperative differentiation between pancreatic duct carcinomas and islet cell tumours 
is of importance, as palliative surgery in patients with islet cell tumours is not only of value 
to relieve clinical symptoms but also because a decrease in the tumour burden, which might 
enhance the effect of treatment'. 
Recently we developed a technique for the visualization of islet cell tumours which is 
based on the presence of somatostatin receptors (SS-R's) on these tumours2~9. The primary 
tumours, as well as previously often unrecognized distant metastases were visualized at 
somatostatin receptor scintigraphy (SRS) in 80% of 25 consecutive patients9. In the present 
study the value of this technique was evaluated in 26 patients with suspected exocrine 
pancreatic duct carcinomas. The results of this in vivo technique were correlated with the 
results of in vitro receptor autoradiographic studies in tumour specimen. Our previous studies 
did not demonstrate the presence SS-R's in human pancreatic duct adenocarcinomas lO • 
The prognosis of exocrine and endocrine pancreatic cancer differs considerably. Because 
of the difference in biological behaviour, a three year survival of patients with known 
metastases from pancreatic duct cancers is rarell - 14 , while in general it can be expected for 
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islet cell carcinomas 1s. 17 . Therefore we carried out SRS in the 12 survivors, who were alive 
three years or more after subtotal (Whipple procedure) or total pancreaticoduodenectomy 
performed for pancreatic duct adenocarcinoma. 
Patients 
Twenty-six patients with primary pancreatic duct cancers (mean age 64 years [ range 
42 to 81]) were studied. After clinical and laboratory investigations in search for a primary 
tumour in the pancreas all patients underwent ultrasonography, CT scanning and ERCP. 
Whenever possible cytology of the tumour was obtained. After informed consent to participate 
in this study, SRS was performed after bowel preparation on an outpatient basis. Without 
taking into consideration the result of the scintigraphy, 22 patients were subsequently operated 
upon for suspected pancreatic duct carcinoma. Four patients were not operated because of 
cytologically proven metastatic disease. 
Tumour tissue specimens from these 22 operated patients were stained with 
haematoxylin-eosin and examined for homogeneous cell structure and characteristic growth 
patterns of exocrine and endocrine tumours. The Grimelius silver staining technique was 
used, as'weU as immunocytochemical staining with antisera against neurone-specific enolase 
(NSE) and chromogranin A to confirm a possible endocrine nature of the tumours. In addition 
immunocytochemical staining with antisera against insulin, gastrin, pancreatic polypeptide 
(PP), vasoactive intestinal polypeptide (VIP), somatostatin, glucagon and neurotensin was 
performed. Tumours were histologically classified by one pathologist, who was not informed 
about the SRS results. Whenever enough tumour tissue was available, the presence of SS-R's 
were studied by in vitro autoradiography on cryostat sections as has been described 
previouslyl8. 
Another group of twelve patients who were still alive more than 3 years after subtotal 
(n = 10) or total (n =2) pancreaticoduodenectomy performed for pancreatic duct 
adenocarcinomas also underwent a SRS. Five of these patients were known to have metastatic 
disease at the time when SRS was performed. Revision of the tumour blocks of these patients 
which had been previously reviewed by other pathologists took place in the same manner as 
described above. No autoradiography could be done any more on these tumour specimens. 
Materials and Methods 
Material 
The somatostatin analogue [DTPA-D-Phel]-octreotide was obtained from Mallinckrodt 
Medical BV, Petten, Netherlands. [DTPA-D-Phel]-octreotide was labelled with "ultra-pure" 
lllIndium obtained also from Mallinckrodt Medical BV (petten, The Netherlands). The 
labelling procedure has been described elsewhere l9 . Doses ranged from 222 MBq to 272 Mbq 
[lllIn_DTPA_ D-Phel]-octreotide. 
87 
Scintigraphy 
After bowel preparation (2 litre PEG [polyethyleneglycol]) planar or SPECT (single 
photon emission computed tomographic) images were obtained with a large field of view 
gamma camera (Counterbalance 3700 , Siemens Gammasonics, Erlangen, Germany) equipped 
with a parallel-hole collimator as described previously'~21, 
Results 
[111jn-DTPA-Phel]-octreotide scintigraphy (SRS) was carried out preoperatively in 26 
patients with suspected pancreatic duct carcinomas, None of these tumours or their metastases 
could be visualized, ,Twelve patients were subsequently treated by a Whipple procedure, 2 
by total pancreatectomy, 2 patients had a palliative procedure (gastroenterostomy and/or 
choledocho-duodenostomy) after transduodenal biopsy was performed and 6 patients had a 
biopsy only been done, Four patients were not operated since cytology of suspected lesions 
in the liver showed adenocarcinoma, Pancreatic duct carcinoma was found in 18 patients 
operated upon. None of these tumours showed neuroendocrine characteristics. In 16 of these 
tumours autoradiographic studies of the surgical removed tumour tissue could be done and 
no SS-R's were present. In 2 patients the tumour was so extensive that no resection could be 
done, transduodenal biopsies in these two patients however showed atypia without any 
evidence of infiltrating tumour cells, which must be considered a sampling error, The other 
2 patients underwent a Whipple procedure for chronic pancreatitis. In these patients also no 
abnormalities were detected at SRS, No autoradiography was done on the tissue of these 
patients, 
Since long term survival of patients with pancreatic duct carcinoma is rare we looked 
in retrospect at our group oflong-term survivors after surgery for pancreatic duct carcinomas. 
Long term survivors were defined as patients who lived more then 3 years after the primary 
operation, Out of 62 patients, who had been operated between 1985 to 1990, 12 patients were 
found to be alive for three or more years, Five of these twelve patients were known to have 
metastases, These 12 patients underwent SRS, In 7 patients no abnormalities were seen, while 
also other investigations suggested that these patients were tumour-free at that moment 
However in 5 !1 survivors" in whom the presence of metastases was known, all metastatic 
lesions, as well as a number of additional tumour sites were visualized at SRS, Examples of 
the scintigram obtained in one of these patients is shown in figure [. 
Revision of the original tumour blocks including the additional staining procedures 
mentioned above demonstrated that these 5 patients in retrospect were operated primarily for 
"non-functioning" islet cell tumours, In the group of 7 patients without known metastases, 
and without abnormalities at SRS revision of the pathology confirmed that these patients 
indeed had been cured from pancreatic duct canceL 
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Figure I. 
24 hours planar anterior abdominal and upper thoracic. right lateral skull /11 In-DTPA-
D-PheIJ-ocrreofide scintigram of a patient with a metastasized "non-functioning" 
pancreatic tumour 
(a) Note the hotspot in the pancreatic region and the non-homogeneous distribution of 
radioactivity in the liver, indicating the presence of the primary pancreatic tumour and 
the presence qf liver metastases. 
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Figure I. 
(b) Left Supraclavicu/air lymphnode (Virchow) metastases in the same patient. 
Infigure II the scintigram of a 81 year old patient is shown, who was known to have 
a pancreatic tumour. The accumulation of radioactivity in the pancreatic region indicates an 
endocrine nature of the pancreatic tumour. The survival of more than 3 years and the good 
clinical condition after the tumour was diagnosed in this patient confirms the hypothesis. The 
patient refused to undergo an operation or biopsy. 
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Figure ll. 
24 hours planar anterior abdominal /"jn-DTPA-D·Phe 1j-octreoride scintigram of a 
patient one year after a pancreatic tumour was diagnosed. The modest accumulation of 
radioactivity between the kidneys (arrow) indicates (he presence of a neuroendocrine 
tumour in {he region (?f the pancreas. 
Discussion 
It has been previously hypothesized that the in vivo visualization of SS-R positive 
tumours with SRS is more sensitive than in vitro autoradiography because the first technique 
investigates the presence of these receptors three-dimensionally in the entire tumour, whereas 
in the second technique sections of parts of the tumour are studied only two-dimensionally'''. 
Therefore in the present study we investigated whether it might be possible to detect SS-R·s 
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in vivo on human pancreatic duct cancers, despite the fact that no SS-R's had been found in 
vitro in a previous studyl°. The present results demonstrate the absence of SS-R's in all tested 
human pancreatic duct adenocarcinomas in vivo and in vitro. In both instances studies were 
carried out with the somatostatin analogue octreotide which has been reported to bind only 
to part of the SS-R subtypes, cloned in human tissues23•24 • Previous studies by Schally's group 
suggested that human pancreatic duct cancers express low numbers of low affinity SS-R's 
which bind other analogues like RC-16025 Therefore our studies do not allow a definitive 
conclusion for the absence of certain SS-R subtypes on this cancer type. The finding of 
SS-R's on metastases of the islet cell tumours in 5 patients who originally were thought to 
have ductal cancers but who were still alive 3 years or more after the initial operation 
supports the concept that this type of clinically "non-functioning" neuroendocrine tumours are 
rather slow-growing, well differentiated tumour types. Most islet cell tumours (75 %) present 
clinically with symptoms and signs related to the hormonal hypersecretion by these 
tumours"·27. Less frequently symptomatology is related to tumour mass, as is often the case 
in patients with pancreatic duct tumours. Preoperatively it is difficult to differentiate between 
ductal and islet cell tumours. Since it is well known that patients with islet cell tumours may 
benefit from palliative surgeryl, preoperative differentiation is of importance. In our previous 
study' all "non-functioning" islet cell tumours contained SS-R's and could be visualized at 
SRS. 
The present study supports the concept that SRS may have a place in the preoperative 
differential diagnosis of endocrine Hnon-functioning" islet cell tumours and pancreatic duct 
cancers, as well as in the follow-up, especially in those cases in which the pathological 
examination of the tumour tissue had not included special staining procedures for 
neuroendocrine characteristics. OUf results also indicate that the evaluation of the results of 
investigations on the role of surgery and/or radiochemotherapy in pancreatic duct cancer have 
to be interpreted with caution, if no histology and staining for neuroendocrine characteristics 
was performed. 
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CHAPTER VIII 
OCTREOTIDE THERAPY FOR LIVER METASTASES AFTER 
RESECTION OF A NON-FUNCTIONING ISLET CELL TUMOUR 
Eur J Surg Oncology in press 
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Abstract 
A case of chronic gastrointestinal bleeding occurring from a "non-functioning" islet cell 
tumour is reported. Surgical resection was performed although liver metastases were found 
during operation. Postoperative treatment was started with octreotide based on proven 
somatostatin receptors found on the primary tumour. 
The case reviewed is notable for its long symptom free interval and supports a role for 
somatostatin and its analogues in the diagnosis and treatment of" non-functioning" islet cell 
tumours. 
Introduction 
Endocrine pancreatic tumours or islet cell tumours constitute a small, but important 
group of pancreatic tumours. The annual incidence of islet cell tumours was found to be 
0.41100.000 population!. Most of these tumours produce multiple hormones, but usually 
excessive secretion of one hormone predominates, causing specific clinical symptomato-
logy '.3 However, about 15-40% of islet cell tumours do not give rise to hormone-related 
symptoms and are therefore called "non-functioning,,4.,. The reasons why they are clinically 
silent include, the absence of the release of produced hormones, the production of biologically 
inactive pro-hormones, the production of hormones which do not cause clinical symptoms 
(pancreatic polypeptide,chromogranin A), downregulation of hormone receptors and/or the 
production of inhibitory hormones such as somatostatin6 • Most patients with "non-functioning" 
islet cell tumours have rather uncharacteristic symptoms at presentation. The correct diagnosis 
is therefore made at a late stage when extensive tumour growth has occurredV,g. In general 
islet cell tumours grow slowly, but the significantly shorter survival of patients with "non-
functioning" islet cell tumours in comparison with those which cause signs and symptoms of 
hormonal secretion indicates a more malignant behaviour of this subtype', but might also be 
due to the fact that they are diagnosed later. In 70% to 80% of the cases liver metastases are 
present at the time of diagnosis. In early stages, curative resections can be achieved, but here 
we report a case, which suggests that palliative surgery is not only of value to relieve clinical 
symptoms but that a decrease in tumour burden also facili tates the effect of adj uvant therapy. 
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Case report 
In july 1991 a 59 year old man presented with a history of weariness, nausea and 
tiredness. Weight loss during the last 4-6 months amounted to 10 k. He was pale, had a low 
haemoglobin (6.8 mM/I) and a positive faecal haemocult (3x) . Gastroduodenoscopy revealed 
an ulcerating tumour in the second part of the duodenum. Ultrasonography and CT scan 
showed a tumour in the head of the pancreas involving part of the duodenum. No signs of 
lymphnode or liver metastases were seen . Serum gastrin levels were normal. Biopsies taken 
during duodenoscopy showed a neuroendocrine turnOUT, which was positive for chromogranin 
A, neuron specific enolase, synaptophysin and somatostatin, while the tumour was also 
positive in the Grimelius si lver strain. Somatostatin receptor (SS-R) scintigraphy with 222 
MBq [" 1In-DTPA-D-Phe1j-octreotide has been performed as previously described'. Planar 
scintigraphy visualized an area of increased activity in the region of the primary tumour but 
no distant metastases were found, especially the liver showed a homogeneous distribution of 
radioactivity. However, single photon emission computerized tomography (SPECT) with 
radiolabelled octreotide demonstrated several hotspots, both in the region of the pancreas and 
in the liver.(fig.l) Laparotomy was undertaken and multiple small lesions « 5mm) were 
seen macroscopically throughout the liver. Frozen liver sections showed the same type of 
tumour as found in the duodenum and in the head of the pancreas. To prevent further blood 
loss from this tumour a pyloric preserving pancreaticoduodenectomy was performed. 
Figure I. 
(a) 24 hours rransversal SPECr images Qf a parienr wirh a merasrasized "non:funcrioning" 
islet cell tumour showing a horspor ar rhe side ofrhe primary rumour in rhe caput of the 
pancreas (arrow) berween rhe kidneys. 
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Figure I. 
(b) Many hOI spots (yellow) in the liver representing metastases (sp/een in white). 
Histology demonstrated a pancreatic islet cell tumour (jig. II andflg.lIl) with multiple 
smalllymphnode metastases. Autoradiography showed a dense and homogeneous distribution 
of somatostatin- 14 and octreotide receptors throughout the tumour. After an uncomplicated 
postoperative course the patient started with adjuvant therapy with 100 mcg octreotide 3 times 
daily, subcutaneously . Routinely performed ultrasonography every 3 months still did not 
reveal liver metastases or evidence of locoregional recurrence. 
In november 1993 the patient was in a good clinical condition. He did not have side 
effects of the octreotide treatment, but he had some complaints from a hernia cicatricialis. 
During the surgical correction of this hernia the abdomen was reexplored in order to 
investigate whether there was evidence of locoregional tumour recurrence. Peroperatively no 
local rec,urrence was found. However the liver metastases were still present with a similar 
size as observed in july 1991. Multiple liver biopsies were taken which showed the same 
characteristics as before. 
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Figure 11. 
Histology of the resected specimen revealed a neuroendocrine tumour infiltrating the 
duodenal wall. The tumour shows epithelial cells in a trabecular pallern with a richly ' 
vascular stroma. The cells sometimes are slightly atypical but are mostly 
monomorphous. Sparse mitoses are found. (HE staining, 400x). 
Figure 111. 
Neuroendocrine tumour: metastases in the liver. Immunoperoxidase staining for 
Chromogranin A (A), Synaptophysin (8), NSE (C), and Somatostatin (D) shows a 
distinct positive staining for allfour antigens (300x) . 
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Discussion 
Pancreatic islet cell tumours have in general a better prognosis than exocrine, mostly 
pancreatre duct adenocarcinomasHu1 , However, in spite of improvements in diagnostic 
methods, the median delay between the appearance of the first symptoms and the diagnosis 
has not been reduced and most patients are encountered when the tumour has reached an 
advanced stage,,7,'. As pointed out by Eriksson et al. 12 there is a need for optimalization of 
screening patients with uncharacteristic abdominal symptoms for the presence of islet cell 
tumours. In addition to the measurements of plasma levels of chromogranin A and pancreatic 
hormones, we use SS-R scintigraphy to demonstrate the presence of such tumours. Also 
previously unknown metastases can be visualized by this method, since in most instances not 
only the primary tumour expresses SS-R's but also its metastases13. 15 , 
Octreotide has been shown to exert a suppressive effect on hormonal hypersecretion by 
islet cell tumours, which contain SS_R'SI6-19, There is little clinical evidence however that 
octreotide can control the growth of islet cell tumours. This might be related to the fact that 
mostly patients with advanced disease were studied20 , In a late stage such tumours may lose 
their SS-R's due to a loss of differentiation into somatostatin negative tumour cell clones21.22, 
Several in vitro studies did show an antimitotic effect of octreotide in cultured islet cell 
tumours"'''. We recently also showed in vivo a SS-R dependent growth inhibitory effect of 
experimental liver metastases by octreotide25 . 
Octreotide only causes minimal side effects, and might therefore be preferred before 
the use of chemotherapeutic agents and/or interferon26. The mechanism of action of octreotide 
in the control of tumour growth inhibition might involve a direct inhibitory effect andlor an 
indirect one which affects autocrine tumour growth factors27 . The reported case shows an 
aggressive surgical approach in the management of a patient with metastatic islet cell 
carcinoma, which resulted in a long stable disease interval after palliative 
pancreaticoduodenectomy. This is in accordance with the suggestions of Norton et al.", who 
observed a longer survival of this type of patients after (extensive) debulking surgery. The 
experience in this patient suggests an inhibitory effect of octreotide on further growth of SS-R 
positive islet cell tumour cells. This, however, cannot be concluded as yet on the basis of one 
case, as some "non-functioning" islet cell tumours grow relatively slowly, and the follow-up 
of the effect of octreotide therapy is only 30 months. 
Also, this study points to the importance of the preoperative differentiation between islet 
cell tumours and ductal adenocarcinomas of the pancreas, since patients with liver metastases 
of the latter type have a median survival of only 4 months". For this differentiation we 
believe that SS-R scintigraphy might be useful. 
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CHAPTER IX 
SOMATOSTATIN RECEPTOR DEPENDENT GROWTH INHIBITION OF 
LIVER METASTASES BY OCTREOTIDE 
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Abstract 
Rats were treated for 4 weeks by intraperitoneal injection of the somatostatin analogue 
oclreotide, (15 I'g twice a day), After intraportal injection of somatostatin receplor (SS-R) 
positive pancreatic lumour cells (CA-20948) and SS-R negative colon tumour cells (CC-531). 
Octreotide significantly inhibited the growth and development in the liver of SS-R positive 
CA-20948 tumour cells. The mean liver weight decreased from 17.9 ± 3.0 g (controls) to 
14.5 ± 3.7 g (p<O.05). No effect of octreotide treatment was found on the growth and 
development of SS-R negative CC-53 I tumour cells in the liver. Mean liver weight was 11.8 
± 4.5 g (controls) versus 14.0 ± 5.7 g. 
Since no difference was observed between control and octreotide treated rats in serum 
levels of growth hormone (GH), prolactin (PRL) and insulin-like growth factor (IGF-I), the 
growth inhibition of SS-R positive CA-20948 tumour cells was not likely to be due to 
inhibition of the secretion of one of these tumour growth factors. 
Our findings suggest that octreotide may be useful for treatment of patients with SS-R 
positive hepatic metastases, which can be demonstrated by somatostatin receptor scintigraphy. 
Introduction 
Several possible mechanisms of action have been postulated for the tumour growth-
inhibitory effect of somatostatin in vilro analogues l·ll Schally et a!. in 1987 demonstrated 
that the reduction of circulating PRL and GH levels by somatostatin might contribute to the 
inhibition of breast and prostate tumour growthl2. Also somatostatin might inhibit local 
growth factor activity, as GH stimulates cell differentiation directly and clonal expansion 
indirectly through local production of IGF_]13.l6 Somatostatin can also have a direct 
antiproliferative effect and it inhibits DNA synthesis and cell replication induced by epidermal 
growth factor (EGF) by preventing centrosomal separationl7 In human pancreatic cancer 
cells, somatostatin activates dephosphorylation of EGF receptors and thereby reverses the 
stimulatory effect of EGF on cell growthl,.19. Another possible mechanism by which 
somatostatin analogues might inhibit tumour growth is interference with the secretion of 
autocrine growth factors by tumour cells 17 ,2l1.21 or by direct inhibition of angiogenesis22.23 . 
Following treatment with somatostatin analogues an increase in natural killer cell 
activity was reported in man24 and a stimulation of the activity of the reticuloendothelial 
system in rats) indicating that a change in immunological activity might also explain part of 
the tumour growth inhibitory effects'. 
Octreotide has been found to significantly reduce the growth of tumour in the liver 
following intraportal injection of Walker cells into rats but it had no effect on the growth of 
tumours after injection of these cells into the thigh. This was explained by postulating a 
stimulating effect of octreotide on the reticulo-endothelial system (RES), andlor a reduction 
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in hepatic and tumour blood flow". RC-160, another somatostatin analogue, also significantly 
inhibited the incidence and growth of liver metastases of colon 320 DM and WidR human 
colon-cancer cells in nude mice26 . 
Recently a technique for the in vivo visualization of SS-R positive endocrine tumours 
and their metastases has been developed. A parallel between the presence of SS-R on tumours 
and the in vivo and in vitro effects of octreotide on hormonal release from these tumours was 
found, suggesting that a positive scan predicts a good suppressive effect of somatostatin 
analogues". Therefore in the present study we investigated: 1) whether the growth and 
development of hepatic metastases could be inhibited by octreotide, 2) whether this was 
related to the presence of SS-R on the tumour cells and 3) whether this could be due to the 
inhibition of possible tumour growth factors. 
Material and Methods 
Animals 
Male rats of the inbred WAG and Lewis strains, weighing 250-300g, were obtained 
from Harian-CPB (Austerlitz, the Netherlands). The animals were bred under specific 
pathogen-free conditions and were 10 to 14 weeks old when used. The animals were kept 
under standard laboratory conditions (12 hours lightll2 hours dark) and were fed a standard 
laboratory diet (Hope Farms, Woerden, The Netherlands). 
Tumours 
CC-531 is a 1,2 dimethylhydrazine-induced, moderately differentiated colon 
adenocarcinoma, transplantable in syngeneic WAG ratsn. The tumour was maintained in 
RPM! 1640 medium supplemented with 5% fetal calf serum (virus and mycoplasma 
screened), 1 % penicillin (5000 Vlml), I % streptomycin (5000 U/ml) and 1% L-glutamine 
(200mM). All supplements were obtained from Gibco (Breda, The Netherlands). Before their 
use cells were trypsinized (5 min. ,3rC), centrifuged (5 min., 700xg), resuspended in RPMI 
1640 and counted. Viability was measured with trypan-blue exclusion (0,3% in a 0,9% NaCl-
solution). Viability always exceeded 95%. The tumour is immunogenic as determined by the 
immunization-challenge method of Prehn and Main29 . 
The pancreatic tumour, CA-20948, which we derived from Dr. Klijn" was originally 
induced by azaserine. The tumour is of acinar origin and is maintained in OUf laboratory as 
a transplantable tumour in Lewis rats. The tumours were removed from the rats, washed in 
ice-cold RPM! 1640 supplemented with antibiotics and chopped into small fragments which 
were passed through a 18 gauge needle. The resulting slurry was incubated for 10 min. in 
RPM! 1640, centrifuged at 500 g for 5 min. and washed twice with cold medium. The pellet 
was resuspended and adjusted to a suspension containing 200x 10' living cellslml. 
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55 receptor binding studies 
Reaction conditions were the same as those described by Reubi30 . The radioligand used 
in the binding studies was the radiolabelled somatostatin analogue ['251_ Tyr'Loctreotide (SMS 
204-090; Sandoz, Basel, Switzerland). Briefly, membrane preparations (corresponding to SO 
I'g protein) of CC-S31 colon and CA-20948 pancreatic tumour cells were incubated in a tota! 
volume of 100 1'1 RPMI at room temperature for 90 min. with 30,000-SO,000 cpm 
radioligand and increasing concentrations of unlabelled Tyr'-octreotide in HEPES buffer 
(IOmM HEPES, SmM MgCI, and 0,2g/l bacitracin, pH 7,6) containing 0,2% BSA (Sigma). 
After the incubation, I ml ice-cold HEPES buffer (Ph 7,6) was added to the assay mixture, 
and membrane-bound radioactivity was separated from unbound by centrifugation during 2 
min. at 14,000 rpm in an Eppendorf microcentrifuge3i • The remaining pellet was washed 
twice with ice-cold HEPES buffer, and the final pellet was counted in a gamma counter. 
Specific binding was taken to be total binding minus binding in the presence of 10 I'M 
unlabelled Tyr'-octreotide. Unrelated compounds, such as thyrotropin-releasing hormone 
(TRH), luteinizing hormone-releasing hormone (LHRH), and epidermal growth factor (EGF), 
added in a 1000-fold excess were not able to displace ['25I-Tyr'l-octreotide binding. SS-R 
receptor binding data were analyzed by the method of Scatchard plot". 
Induction and measurement oj liver metastases 
Metastatic tumours in the liver were established for both cell lines in 16 rats. After each 
rat was anaesthetized, a 2.5 em median incision was made to expose the portal vein, then 
1.2xlO' viable CA-20948 cells in 0.6 ml HBSS or SxlO' CC-S31 cells in O.S ml HBSS were 
injected slowly into the portal vein, and the abdominal wall was closed using one layer of 
continuous silk suture. 
After injection of tumour cells, the rats were divided into several groups as follows: (I) 
CC-S31 liver metastases treated with octreotide (8 WAG rats); (2) CC-S31 liver metastases 
used as controls (8 WAG rats); (3) CA-20948 liver metastases treated with octreotide (8 
Lewis rats): (4) CA-20948 liver metastases used as controls (8 Lewis rats). 
After 28 days all rats were killed by an overdose of ether for evaluation of the incidence of 
liver metastases. The livers were dissected and fixed in 10% formalin overnight. The visible 
tumours on the surface of each liver (up to SOO) were counted and scored and finally all livers 
were weighted. 
Treatment with the somatostatin analogue octreotide 
The somatostatin analogue octreotide (D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol) 
(Sandoz, Basel) IS I'g was injected intraperitoneally twice daily (approximately ±SO I'g/kg) 
starting on the first day after tumour implantation in rats of groups I and 3. The dose of 
octreotide was chosen on the basis of a previous study33 on the effects of octreotide on growth 
of 731Sa pituitary tumour cells in rats. 
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Assays 
Plasma of 16 rats (8 controls and 8 treated with octreotide 15 I'g twice daily i.p.) were 
collected 4, 11 and 18 days after starting the administration. PRL and rat GH concentrations 
were determined by a double antibody radioimmunoasay, as described previously"·". 
Concentrations of IGF-I were measured by radioimmunoassay using a commercially available 
kit from Medgenix Diagnostics (Brussels, Belgium). 
All data are expressed as means (s.e.m.). Statistical analysis was performed using the 
Mann-Whitney U test. P < 0.05 was considered significant. 
Results 
SS receptor binding studies 
Specific binding of the 125I-labelled somatostatin analogue Tyr'-octreotide to membrane 
preparations of CA-20948 pancreatic tumour cells was demonstrated, but not to the CC-531 
colon tumour cells. Figure I shows the binding [' 25I-Tyr']-octreotide to membranes of CA-
20948 (0) and CC-531 (A) tumour cells and on rat brain cortex (0), which were functioning 
as a control. Binding of [' 25I-Tyr']-octreotide to CA-20948 membranes was specific and could 
be displaced in a dose-dependent manner with unlabelled Tyr'-octreotide. Scatchard analysis 
of these data revealed a single class of high affinity binding sites with an apparent dissociation 
constant (Kd) of 0.6 nmolll and a maximum binding capacity (B",,,) estimated to be 110 
fmollmg per membrane protein.(table 1) 
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Table 1. Dissociation constant (K,J and maximum binding capacity (BmaJ qf SS·receptors. 
Cell type K,(nmol/l) Bmax (fmol per rng 
membrane protein) 
CA·20948 0.6 110 
CC-53 I n.d n.d 
Brain cortex (control) 1.2 243 
n.d.:not detectable 
Effect of octreotide on the incidence of liver metastases 
The number of hepatic metastases of CA-20948 pancreatic tumour cells was 
significantly reduced after 28 days of treatment with octreotide. The median number of liver 
tumours was 286 (range 146 to greater than 500) in treated rats and more than 500 (range 250 
to in excess of 500) in controls (P < 0.05). This difference in tumour load also recurred as 
a difference in mean (s.e.m.) liver weight (14.5 (3.7) g in animals given octreotide and 17.9 
(3.0) in controls). (table 2) Regression analysis of liver weight and the number of metastases 
produced a correlation coefficient of 0.95 (P<O.OI). 
Rats injected with colonic tumour cells (CC-531) showed no significant difference in 
the number of liver tumours (median (range) 6.5 (0-425) in the treated animals and 11.0 (0-
475) in the controls) and the mean (s.e.m.) liver weight (14.0 (5.7) g in the treated animals 
and 11.8 (4.5) in the controls). 
Table 2. Incidence of hepatic metastases lifCA-20948 and CC-53] cancer cells treated with 
octreotide. 
Tumour cell line Me:m(s.e.IU.)liver 1\'0. of tumours 1\'0. of 'Ul.iUlal~ with liver hunours 
and treatment weight (i!) Yledian (nUlge) o tumour 1-100 tUlllours 100-500 hun ours ~500 tUlllOUrs 
CA-20948 
Coutrol~(n=8) 17.9 (3.0) > 500(250- > 500) 0 0 3 S 
Octreotide lSp.g 14.5 (3.7)" 286(146->500)' 0 7 
twice daily(u""S) 
eC-531 
Controls(n=8) 11.8 (4.5) 11.0 (0-475) 4 2 0 
Octreotide 15~ 14.0 (S.7)" 6.5 (0-425)- 2 3 3 0 
t",ice diilly(u",,8) 
'p < 0.05, "not sigl1ifimnt (versus COlltrol~, l\1~UUl_ Whitney U tell) 
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Effects of octreotide on Glf, PRL and IGF-/ release 
Plasma levels of growth hormone (GH), prolactin (PRL) and insulin-like growth IGF-I) 
factor-I were not affected by chronic administration of octreotide.(table 3). 
Table 3. Effect of the administration for 28 days of octreotide (2x15 p.g/day) on plasma 
PRL, Glf and IFG-I levels. 
Growth Insulin-like 
Prolactin hormone growth factor-I 
(p.g/l) (p.gll) (nnmolll) 
Day 4 
Controls(n=8) 12.4(8.6) 10.4(6.3) 108.0(11.5) 
Octreotide( n = 8) 11.4(8.1) 9.5(6.7) 99.8(10.6) 
Day 11 
Controls(n = 8) 9.6(6.4) 3.4(1.7) 108.9(11.0) 
Octreotide(n =8) 11.7(7.5) 2.8(2.0) 100.9(10.7) 
Dayl8 
Controls(n = 8) 10.3(6.9) 5.6(4.0) 103.8(11.6) 
Octreotide( n = 8) 9.7(7.10) 5.1(3.1) 92.1(13.3) 
Values are means (s.e.m.) 
Discussion 
Several studies have demonstrated that somatostatin analogues inhibit tumour growth 
in experimental tumour models l-9. Most tumours used in these experiments contain 
somatostatin receptors and were studied in vitro and in vivo as a transplantable tumour. Nott 
et a1. reported on the effects of octreotide on a hepatic tumour derived from intraportal 
administration of Walker cells10•2'. They suggested that the inhibitory effect by octreotide was 
related to the location of the Walker cells within the liver, since they showed that octreotide 
stimulated the activity of hepatic RES by 300%. Kupffer cells and large granular lymphocytes 
form an important natural defence against malignant cells in the liver. A reduced portal 
venous flow and splanchnic vascular resistance in octreotide treated animals, both decreasing 
the supply of nutrients in the early stages of development of hepatic tumour, was also found 
by these authors". RC-160 can also inhibit the incidence and growth of liver metastases of 
two human colon cancers, by reducing the bromodeoxyuridine labelling index and DNA and 
protein contents of the tumour suggesting a cytostatic effect of RC-160 on cellular 
proliferation" . 
Another possible mechanism of antitumoural action of somatostatin analogues includes 
the interference with growth factor secretion such as PRL, GH and IGF-I. The reduction in 
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PRL levels produced by the administration of octreotide in animals may contribute to the 
inhibition of the growth of experimental breast and prostate tumours12 The fall in GH levels 
could also directly or indirectly be of importance for the inhibition of growth of various 
tumours. Secretion of IGF-I, which mediates most of the effects of growth hormone at tissue 
levels and also induces differentiation and proliferation of mesenchyme derived cells is also 
indirectly inhibited by somatostatin analogues13-16 • A decrease in the concentration of lGF-I 
or suppression of its activity might therefore reduce or prevent its mitogenic effects shown. 
The results of our study show that octreotide significantly reduces the growth and 
development of hepatic tumours derived from intraportal injection of SS-R positive CA-20948 
pancreatic cells, but not of SS-R negative CC-531 colon cells. Since no difference was found 
between serum levels of PRL, GH and IGF-I during treatment with the somatostatin 
analogue, the mechanism by which tumour growth inhibition of CA-20948 cells was observed 
seems to be SS-R dependent and not only influenced by the stimulation of the RES system 
or by reduction in portal flow because no inhibition of growth was seen of SS-R negative 
CC-531 hepatic metastases. If any immunomodulation would have taken place, growth 
inhibition of CC-531 cells might have been expected since they are known to be 
immunogenic36.37 . 
Recently we described the use of isotope labelled somatostatin analogues for the 
visualization of neuroendocrine tumours as well as their metastases27 . In vitro detection of 
SS-R on these tumours indicated that the ligand binding to the tumour ;n vivo indeed 
represents binding to specific SS-R's. The detection of SS-R predicted a good suppressive 
effect of octreotide on hormonal hypersecretion by these tumours. The results of the present 
study indicate that octreotide might be considered as a potentially useful agent for the 
treatment of patients with SS-R positive liver metastases from neuroendocrine tumours, 
especially since no side-effects were observed in patients using octreotide38 . 
In conclusion, we have demonstrated that the somatostatin analogue octreotide inhibits 
the growth and development of hepatic tumours of SS-R positive CA-20948 pancreatic cells. 
Our findings suggest that this is mediated via a SS-R dependent mechanism, since no 
inhibition could be found of SS-R negative CC-531 colon cells and no difference in 
circulating hormones and growth factor was observed. Further clinical studies are required 
to investigate the potential use of octreotide in patients with SS-R positive liver metastases. 
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CHAPTER X 
GENERAL DISCUSSION 
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Some 20 years after the isolation and characterization of somatostatin, five subtypes of 
somatostatin receptors (SS-R's) were also identified. Ligand-binding and autoradiographic 
studies demonstrated SS-R's on a variety of human, mostly neuroendocrine tumours. In this 
thesis the in vivo detection of SS-R's (probably only SSTR2-R's) in breast cancer, and islet 
cell tumours is described, while aspects of the pathophysiological role of these SS-R's was 
studied. 
Forthe visualization of SS-R positive tumours we used [IIlIn-DTPA-D-Phe1]-octreotide, 
since there are several arguments that octreotide scintigraphy represents SS-R imaging. First 
of all pretreatment with high doses of unlabelled octreotide prevents tumour uptake of [111In-
DTPA-D-Phe1]-octreotide in rats bearing SS-R positive tumours. Autoradiographically it was 
also found that only the anterior lobe of the rat pituitary, which is the only part of this organ 
with SS-R's, showed specific binding of the radioligand after its injection. As has been found 
in our study as well, a close relation exists between the presence of SS-R's, demonstrated 
with in vitro autoradiography and the visualization of tumours and diseases by in vivo 
octreotide scintigraphy. 
Despite the many promising reports on the potential benefit of radiolabelled monoclonal 
antibodies for in vivo tumour detection, their widespread application has been hampered for 
several reasons. The low tumour background ratios achieved with this technique is due to the 
large molecules often used, which lead to a high background. Because of the rapid clearance 
of the small sized C"ln-DTPA-D-Phe1]-octreotide by the kidneys, much higher tumour to 
background ratio can be obtained. Antibody formation, which can often be found after 
administration of monoclonal antibodies, is extremely rare in patients treated with octreotide. 
Therefore the SS-R imaging can easily be repeated without any risk of an anaphylactic 
reaction. 
On the basis of specific binding between octreotide and its receptor it turned out to be 
possible to visualize primary breast cancers, as well as islet cell tumours with radiolabelled 
octreotide scintigraphy. Also undetectable metastases could be detected. 
For breast cancer it was demonstrated that somatostatin analogue receptor scintigraphy 
can visualize recurrent disease very early, visualization at a stage when patients are without 
clinical symptoms, and when commonly used serum tumour markers are (still) normal. At 
present it is unclear whether early detection of recurrent disease is of clinical value. 
Theoretically early detection is beneficial because it is well known that chemotherapy is more 
effective in patients with a low tumour burden, although "low" has not been defined. 
Somatostatin has been shown to exert tumour growth inhibitory effects, probably mainly 
via membrane SS-R's. Therefore a randomized controlled prospective study is justified 
comparing chemotherapy or tarnoxifen alone versus chemotherapy or tarnoxifen in 
combination with octreotide in patients with SS-R positive recurrent metastatic disease. The 
effect of chemotherapy on SS-R expression will be important for the results of such a trial, 
since one might expect no significant different between the two groups if chemotherapy 
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causes loss of SS-R expression. Moreover a study concerning radiotherapy with a 
radionuclide coupled to somatostatin might be considered in such patients. 
The pathophysiological significance of SS-R's on breast cancer remains uncertain. In 
the studies described in chapters III and IV the expression of the somatostatin receptor in 
human breast cancer was investigated in vitro and in vivo, respectively. The consecutively 
collected tumours that were investigated in chapter IV do in part derive from the patients 
under investigation in chapter III. Due to a small difference in the periods that the tumours 
were collected the overlap is not complete. However, the patient and tumour characteristics 
in both studies are comparable. Also the high incidence of somatostatin receptor expression 
in vitro and in vivo corresponds well. Strikingly, the results of both studies suggest opposite 
implication for the patients prognosis. In chapter IV it was suggested that SS-R expression 
might correlate with a favourable prognosis. This was based on the correlation of SS-R 
expression with smaller tumour size. Also, earlier retrospective investigations had reported 
a favourable prognosis in SS-R positive breast cancer. In contrast to these data are the first 
follow up data of the in vivo study that suggest more aggressive disease: out of the 37 patients 
with a SS-R positive tumour, 11 patients were found to have recurrent disease during the 2.5 
years of follow-up, whereas the 17 patients with an initially SS-R negative tumour were all 
without evidence for recurrent disease. These II patients were not characterized by any 
common patient or tumour characteristic that differentiated these patients from the other 
patients with a SS-R positive breast tumour, nor could any specific genetic alteration or 
amplification being found in the tumours. It appears that although SS-R positive tumours 
show a tendency toward better differentiation and smaller tumour size, this by no means 
implicates a better prognosis. A multivariate analysis, with a great number of tumours and 
longer follow-up period is required to show the significance of SS-R expression, and it 
possible correlation with genetic alterations and/or amplifications and prognosis of patients 
with primary breast cancer. 
A relation between neuroendocrine differentiation and SS-R expression has been 
previously reported. In parallel with observations in metastasized colonic and prostatic cancer 
neuroendocrine differentiation might point to a worse prognosis. However, in our study no 
such correlation could be found. In addition, at the genetic level no relation could be 
observed between SS-R expression and alterations and/or amplification of frequently used 
genetic markers in breast cancer. Since no SS-R's seem present in the majority of normal 
breast tissue, SS,R expression might be acquired by tumour cells due to a neoplastic event, 
which results in further proliferation of tumour cells at subsequent stages of differentiation, 
expressing SS-R's. It might also be possible that SS-R expression of tumour cells is caused 
by an alteration in the expression of certain cellular genes whose normal function involve the 
regulation of cell growth. 
In chapter III and IV the expression of the SS-R in human breast cancer was 
investigated in virm and in vivo, respectively. In both studies a high incidence of SS-R 
expression was found. In order to investigate any growth inhibitory effect of the somatostatin 
analogue octreotide on SS-R expressing breast tumours in v;tro, it was first necessary to 
culture the collected primary breast cancer cells which has been proved to be difficult. 
Secondly, since a stimulative effect of tumour-derived fibroblast has been demonstrated on 
malignant breast epithelial cells, we wanted to separate these cells because octreotide may be 
involved in negative growth regulation through tumour-derived fibroblasts. In chapter V the 
results showed the existence of a paracrine growth stimulative mechanism between tumour-
derived fibroblasts and epithelial breast cancer cells. However the pathophysiological role of 
SS-R's and octreotide could not be established but with the possibility of culturing tumour-
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derived fibroblast and human breast cancer cells separately, further studies in this field could 
now be developed. 
The observation made in our study in rats showing SS-R dependent growth inhibition 
of liver metastases by octreotide might contribute to the initiation on of new clinical trials as 
above mentioned for SS-R positive breast cancer patients but also in patients after surgery for 
malignant islet cell tumours. However, since SS-R's are not always found on all tumour cells, 
and might be lost during further dedifferentiation of a tumour, one might only expect 
temporary growth inhibitory effect of somatostatin analogues. 
The sensitivity of the SS-R scintigraphy in localizing islet cell tumours was high, except 
in the case of insulinomas. The presence of other subtypes of SS-R's in this tumour is well 
known and necessitates the development of other isotope-labelled somatostatin analogues. 
Other factors, which in general may interfere with the visualization of neuroendocrine 
tumours include the presence of unlabelled somatostatin e.g. by auto-, para-, or endocrine 
production of somatostatin, or somatostatin analogue administration. In both cases this may 
result in receptor blockade or "down"regulation of the receptor. 
Finally, the difference in SS-R expression between islet cell tumours and pancreatic duct 
cancers seems to offer the possibility to differentiate between these tumour preoperatively. 
This is important, as palliative surgery in patients with islet cells tumours is not only of value 
to relieve clinical symptoms but also because a decrease in tumour burden might enhance the 
effect of medical treatment, resulting in a longer survival. The use of the SS-R scintigraphy 
as a diagnostic technique for suspected islet cell tumours, is favoured by its harmless, non-
invasive nature. In islet cell tumours ultrasound and CT are usually limited to the pancreas 
and liver region, thereby missing possible metastases. Intra-operative ultrasound and surgical 
palpation are probably the best methods to localize the tumour, therefore the SS-R 
scintigraphy should not be performed to localize the tumour but only to support diagnosis of 
an islet cell tumour and for directly staging the patient. 
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SUMMARY 
Somatostatin, a hormone which has an inhibitory influence on several physiological 
processes, is a small peptide consisting of 14 amino-acids, and was first isolated from the 
hypothalamus of the rat. Soon after, somatostatin was found in numerous other organs, such 
as the brain, stomach, intestines, pancreas, thyroid, thymus and bronchi, from which it could 
be extracted. Natural somatostatin has a very short half-life and can only be administered 
intravenously. The development of several longacting analogues of somatostatin facilitated 
diagnostic procedures and therapy involving somatostatin and its receptors. 
One of the first and best known effects of the hormone somatostatin is inhibition of the 
release of growth hormone by the pituitary gland. Other, mainly inhibitory effects of 
somatostatin have been described recently, including a direct inhibitory effect on the growth 
of tumour cells. Somatostatin receptors (SS-R's), present on tumour and pituitary celis, 
mediate this inhibitory effect as well as release of growth hormone. The analogue octreotide, 
used in this study, binds to SS-R's on normal and tumour cells. Autoradiography, using '251_ 
Tyr-octreotide, was utilized to localize receptors for somatostatin in vitro. These receptors 
were found in several neuroendocrine tumours, as well as in breast carcinomas and islet cell 
tumours of the pancreas. 
The aim of this study was to assess the possibility of visualizing SS-R's in vivo, using 
octreotide labelled with radioactive "'Indium and diethylene-triaminopentaacetic acid (DTPA) 
as a carrier (octreoscan). 
The octreoscan visualized the primary tumour in 37 out of 50 patients with primary 
breast carcinoma. Autoradiography of the resected tumours confirmed the findings of the 
octreoscan. During follow-up, the octreoscan proved able to detect metastases in several 
patients, some of whom were asymptomatic or exhibited normal serum levels of tumour 
markers. 
The octreoscan could detect islet cell tumours in 80 % of patients tested. In some cases, 
unknown metastases of these islet cell tumours were visualized by the octreoscan. 
To differentiate pre-operatively between endocrine tumours of the pancreas and 
pancreatic adenocarcinomas, the value of the octreoscan was investigated. In contrast to islet 
cell tumours, none of the pancreatic adenocarcinomas could be visualized by the octreoscan. 
Autoradiography of the resected pancreatic adenocarcinomas did not reveal SS-R's. 
The visualization of SS-R's in vivo can play an important clinical role. Patients with a 
SS-R positive primary tumour can be staged simply and rapidly, early detection of metastases 
is possible and the presence of SS-R's on tumours in vivo may correlate with a suppressive 
effect of octreotide on growth of andlor hormone production by these tumours. The 
octreoscan can help to differentiate preoperatively between endocrine pancreatic tumours and 
pancreatic adenocarcinomas. This differentiation is important because aggressive surgical 
therapy of endocrine pancreatic tumours can improve palliation and prolong survival, as 
illustrated in the case report in chapter VIII. 
To investigate whether some genetic alterations or neuroendocrine differentiation would 
be correlated with SS-R expression on breast cancer cells, SS-R positive as well as SS-R 
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negative breast tumours were analyzed. A correlation between the presence of SS-R's and the 
absence of the retinoblastoma gene (tumour suppressor gene) or altered proto-oncogenes was 
not found. Neuroendocrine differentiation, assessed by Grimelius silver staining and 
immunohistochemical markers, was not seen more frequently in SS-R positive tumours. Other 
genetic alterations may be responsible for SS-R expression. These genetic alterations could 
influence the biological behaviour of this clinically relevant subgroup of tumours. 
The mechanism of inhibition of growth of tumour cells by octreotide was studied in two 
experiments. 
In the first experiment, fresh tissue of primary breast tumours was obtained. The 
tumour cells and the fibroblasts were separated on a gradient, and subsequently cultured. The 
inhibitory effect of octreotide on the growth of tumour cells, due to paracrine and/or 
autocrine growth factors produced by tumour cells or fibroblasts, derived from the same 
tumour, was studied. Fibroblasts proved to promote, as well as inhibit tumour cell growth. 
When epidermal growth factor (EGF) , insulin or oestradiol were added to fibroblasts a 
synergistic effect on the promotion of tumour growth was observed. In one out of six breast 
tumours octreotide inhibited the growth of tumour cells in absence of fibroblasts. In another 
tumour octreotide inhibited the growth of fibroblasts. The model of separating and culturing 
tumour cells allows detailed investigation of the interaction of tumour cells and tumour 
derived fibroblasts, as well as studying a possible inhibitory indirect effect of octreotide on 
tumour growth. 
In a second experiment, the effect of octreotide on the growth of tumour cells in the 
liver was studied. A rat liver metastases model was used. Liver colonies of tumour cells were 
induced by injecting tumour cells in the portal vein. In one group of rats SS-R positive 
tumour cells were used, in another group, SS-R negative tumour cells were injected. After 
intraportal injection of tumour cells, half of the rats was treated with octreotide, the other 
half, with saline. Tumour colonies could be found in the liver of both groups after four 
weeks. The growth of tumour cells in the liver was significantly less in the group of rats with 
SS-R positive tumour cells, that had been given octreotide. No changes of levels of growth 
factors were observed. Therefore, the inhibition of growth of SS-R positive tumour cells in 
the liver seems to be a receptor dependent mechanism. 
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SAMENV A TTING 
Somatostatine is een hormoon dat een remmende invloed heeft op verschillende 
fysiologische processen. Het is een klein eiwit bestaande uit 14 aminozuren en werd voar het 
eerst gejsoleerd uit de hypothalamus van de rat. Spoedig na deze ontdekking werd 
somatostatine oak in andere organen gevonden, zoals hersenen, pancreas, darm ,schildklier, 
thymus, darmen en bronchi, en kon het worden gesynthetiseerd. Een van de eerst ontdekte 
en meest bekende werkingen van somatostatine is remming van de afgifte van groeihormoon 
door de hypofyse. 
Naast somatostatine werden verscheidene langwerkende analogen ontwikkeld, amdat het 
natuurlijke somatostatine een zeer korte halfwaarde tijd heeft en aileen intraveneus kan 
worden toegediend. Andere, voornamelijk inhiberende, effecten van somatostatine zijn de 
laatste jaren beschreven, waaronder een direct groeiremmend effect op tumorcellen. Zowel 
dit groeiremmende effect, als het inhiberend effect op groeihormoon release wordt tot stand 
gebracht via somatostatine receptoren (SS-R's), aanwezig op hypofyse- en tumorcellen. Het 
analogon octreotide, 8 aminozuren lang, bindt eveneens aan SS-R's op zowel normale als 
tumorcellen. 
Receptoren voar somatostatine kunnen op cell en worden aangetoond met behulp van 
autoradiografie met [125I-Tyr']-octreotide. Op vele neuroendocriene tumoren maar oak op 
mammacarcinomen evenals eilandjes tumoren van het pancreas werden deze receptoren 
gevonden. 
Doel van ons onderzoek, beschreven in dit proefschrift, was in eerste instantie de 
mogelijkheid te bestuderen of SS-R's ook in vivo gevisualiseerd konden worden. Hiervoor 
werd gebruik gemaakt van het analogon octreotide waaraan met behulp van diethyleen-
triaminopentaazijnzuur (DTPA) radioactief lllIndium werd gekoppeld (octreoscan). 
Bij 50 patienten met een primair mammacarcinoom was het in 75 % van de gevallen 
mogelijk am de primaire tumor te visualiseren. Autoradiografie op de na operatie verkregen 
tumoren valideerde dat daadwerkelijk SS-R's zichtbaar werden gemaakt. Ook metastasen van 
patienten met een primair SS-R positieve tumor konden tijdens de follow-up worden gevisuali-
seerd, in sommige gevallen nog voordat de patienten symptomen hadden, of tumormarkers 
verhoogd waren. Eilandjes tumoren van het pancreas konden in 80% van de gevallen worden 
gezien evenals vaak nog niet eerder bekende metastasen. 
Om preoperatief te kunnen differentieren tussen endocriene en exocriene pancreas 
tumoren werd de waarde van de octreoscan onderzocht. Alle exocriene pancreas tumoren 
(adenocarcinomen) waren in tegenstelling tot de endocriene tumoren, niet te visualiseren en 
ook bij autoradiografie waren geen SS-R's aanwezig. Het visualiseren van SS-R's in vivo 
heeft mogelijk als klinische betekenis dat, patienten met een primair SS-R positieve tumor 
eenvoudig en snel kunnen worden gestageerd, vroege detectie van metastase mogelijk is en 
dat de aanwezigheid van SS-R's in vivo op tumoren, een voorspellende waarde heeft voor een 
suppressief effect van octreotide op groei van en/of hormoonproduktie door deze (eilandjes) 
tumoren. Ook kan in vele gevallen preoperatief reeds gedifferentieerd worden tussen 
endocriene en exocriene pancreastumoren. Dit is van beJang is voor de therapie, daar een 
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agressief chirurgisch ingrijpen bij endocriene tumoren niet alleen van palliatieve betekenis is, 
doch ook daadwerkelijk de overleving van patienten kan verlengen. Een voorbeeld van deze 
benadering wordt gegeven in het case report beschreven in hoofdstuk VIII. 
Om te onderzoeken of bepaalde genetische afwijkingen, dan weI neuroendocriene 
differentiatie gecorreleerd zijn met SS-R expressie op mammacarcinoom cellen, werden zowel 
SS-R positieve als SS-R negatieve mammatumoren geanalyseerd. De aan- of afwezigheid van 
SS-R's bleek niet gecorreleerd met de afwezigheid van het retinoblastoma gen (tumor-
suppressor gen) , of met, bij het mammacarcinoom veel voorkomende afwijkingen van 
verschillende proto-oncogenen. Neuroendocriene differentiatie, onderzocht met de Grimelius 
zilverkleuring en immunohistochemische markers, werd ook niet vaker aangetoond bij SS-R 
positieve tumoren. Waarschijnlijk zijn andere dan de door ons onderzochte genetische 
afwijkingen verantwoordelijk voor de SS-R expressie en bepalen ook deze afwijkingen het 
biologisch gedrag van deze klinisch relevante subgroep. 
Om een groeiremmend effect van octreotide op tumorcellen aan te tonen werd een 
tweetal experimenten uitgevoerd, welke nog niet eerder zijn beschreven. Allereerst werd 
bestudeerd of het groeiremmend effect van octreotide veroorzaakt werd door inhibitie van 
para- en/of autocriene groeifactoren geproduceerd door tumorcellen zelf of door fibroblasten 
afkomstig van dezelfde tumor. Hiertoe was het noodzakelijk om primaire tumoren in kweek 
te brengen. Primaire mammacarcinomen werden hiervoor vers aangeleverd, waarbij de 
tumorcellen zelf en de van de tumor afkomstige fibroblasten na zuivering apart werden 
geincubeerd. Deze fibroblasten bleken zowel tumorcel groei te kunnen stimuleren als te 
kunnen remmen. Bekende groeifactoren, als epidermal growth factor (EGF), insuline en 
oestradiol hadden een synergistisch effect met deze fibroblasten op tumorcel groei. Octreotide 
remde in een enkel geval de tumorcel groei aIleen in afwezigheid van fibroblasten en bleek 
in een andere cultuur de groei van fibroblasten te kunnen remmen. 
Deze eerste studie toont duidelijk het belang aan van de mogelijkheid om primaire 
mammatumoren in kweek te kunnen brengen en de tumorcellen apart te kunnen incuberen, 
gescheiden van fibroblasten afkomstig van dezelfde tumor. Op deze manier wordt het 
mogelijk om de rol van deze fibroblasten bij tumorcel proliferatie te bestuderen. Ook een 
eventueel indirect effect van octreotide kan op deze manier worden geanalyseerd. ' 
In een tweede experiment werd onderzocht of remming van tumorgroei in de lever door 
octreotide mogelijk was, en afhankelijk was van de aanwezigheid van SS-R's, of dat dit het 
gevolg was van inhibitie van verschillende bekende groeifactoren, zoals groeihormoon, 
prolactine of insuline-afhankelijke groeifactor (lGF-I). Hiervoor werd een lever metastase 
model bij de rat gebruikt. Door in een groep ratten SS-R positieve en in een andere groep 
ratten SS-R negatieve tumorcellen in de vena porta te injecteren, groeiden na enige weken, 
in beide groepen kolonies tumorcellen in de lever. Na intraportale injectie van tumorcellen 
werd de helft van de ratten behandeld met octreotide en de andere helft met fysiologisch zout. 
De uitgroei van leverkolonies was significant minder in de groep van SS-R positieve 
tumorcellen behandeld met octreotide, zonder dat dit het gevolg was van inhibitie van een van 
de eerder genoemde groeifactoren. De inhibitie van SS-R positieve tumorcellen in de lever 
lijkt dus een receptor gebonden mechanisme en verdient derhalve klinische evaluatie. 
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DANKWOORD 
De laatste jaren heb ik ervaren, dat samenwerking tussen verschillende disiplines binnen 
een Academisch ziekenhuis zeer plezierig en vruchtbaar kan zijn. Na het begin van het 
tweede deel van de opleiding tot chirurg, was in eerste instantie Hans Jeekel degene die mij 
stimuleerde om wetenschappelijk onderzoek in de oncologie te gaan doen. Hij is ook 
verantwoordelijk geweest voor mijn komst naar het Dijkzigt ziekenhuis, wat ik tot op heden 
nog geweldig waardeer. De keuze om mijn vervolg opleiding in het Dijkzigt ziekenhuis te 
willen doeo, onder leiding van Kieje Bruining, is nooit een verkeerde geweest. Naast een 
vaak koele heldere k1inicus, heb ik hem gelukkig de laatste jaren ook leren kennen als een 
levensgenietende "tuinman ". 
Voar het beeindigen van mijn opleiding, werd mij de mogelijkheid geboden om samen 
met Hans Jeekel, de verantwoordelijkheid te dragen voor de chirurgische oncologie. De 
manier waarop ik vooral in het begin, maar oak vaak nu nog door Hans word bij gestaan, dag 
en nacht, is moeilijk onder woorden te brengen. Patientenzorg boven alles. Altijd bereikbaar 
voar overleg. Noait te beroerd om "even" mee te kijken. Dank. 
Steven Lamberts bood mij de kans om mijn wetenschappelijke aspiraties verder te 
ontwikkelen. Steven heeft mij op sleeptouw genomen en mij op een verhelderende manier 
ingewerkt in de in dit proefschrift beschreven materie. Gedurende de afgelopen jaren heeft 
hij mij menigrnaal uit een Ildal1etje" weten te hal en wanneer het onderzoek niet direct het 
gewenste resultaat opleverde. Zijn enthousiasme voor het klinisch en wetenschappelijk werk 
is voor mij uiteindelijk doorslaggevend geweest om met veel plezier verder te gaan. Zelfs 
vanuit Amerika volgde hij alles op de voet. Zonder zijn inbreng was dit proefschrift nooit tot 
stand gekomen. 
Yoar het klinische deel van dit proefschrift is een goede samenwerking met de afdeling 
Nucleaire Geneeskunde noodzakelijk geweest. Onder de bezielende leiding van Eric 
Krenning functioneert deze dynamisch afdeling al jaren met veel succes. Een chirurg 
enthousiast maken VDar nucleaire geneeskunde kost ongetwijfeld een hoop energie en geduld. 
Toch is hem dat de afgelopen jaren gelukt en zelfs tijdens een congres in een warm land 
volhardde hij hierin. Zijn hulp bij het afronden van dit proefschrift was niet aileen zeer 
waardevol maar ook plezierig. Ook aile anderen, Wmem Bakker, Peter Kooij, Ambroos 
Reijs, Woul Breeman ("slapie") en Yoe Oei, werkzaam op bovengenoemde afdeling, kon 
ik altijd lastig vall en en stonden altijd direct voor mij klaar. Ook een woord van dank aan aile 
laboranten, in het begin onder leiding van Ina Loeve en later van Marjan Goemaat, die het 
mogelijk maakten dat ik altijd weer mijn patienten er snel tussen kon schuiven. De 
opgewektheid die van jullie afstraalt is een lust voor het oog (vooral in Indonesia). 
Het experimentele werk ging zeker in het begin niet zonder enige tegenslagen gepaard. 
Gelukkig bleefRichard Marquet, met al zijn ervaring, nuchter en trok iedere keer weer een 
nieuw plan. Uiteindelijk lukte het dan toch om een experimenteel model te vinden waar mee 
gewerkt kon worden. Het uitwerken en publiceren van de onderzaeksresultaten, heb ik voar 
een groot deel aan hem te danken. Ook voor de "finishing touch" was zijn hulp onont-
beerbaar. lneke Hekking en Wil Kort, dank voor de inzet tijdens de aanvang van de 
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experimenten, die de basis waren voar het definitieve model. Gerrit Slooter speelde een 
belangrijke ral bij het uitvoeren van vele experimenten. 
Het overleg met Leo Hofland en Aart Bootsrna over hun bijdrage aan dit proefschrift 
is voor mij a1tijd een uitdaging geweest. Om met zulke wetenschappers te werken en van 
gedachten te wisselen was uitermate prettig. Hun inbreng heeft uiteindelijk geleid tot twee 
hoofdstukken, die dit proefschrift completeren. 
Zander pathologie was oak dit proefschrift niet tot stand gekomen. Rene van Pel, Fre 
Bosman en Jan den Hollander waren de beaordelaars van aIle mamrna- en pancreasprepa-
raten. Op hun afdeling is mij al vele malen gevraagd of ik daar oak een kamer heb, zovaak 
moest ik hun lastig vallen. Het verblijf in Bern bij Jean-Claude Reubi am iets van 
autoradiografie te leren, heef! mij toen doen beseffen wat een voorwerk hij verricht heeft en 
nu, hoe dankbaar ik moet zijn am van zijn diensten gebruik te hebben mogen maken. 
Tot slot een woord van dank aan mijn " pijlerhoofd" Ruud Schouten, waarmee het niet 
aileen fijn samenwerken is, maar die oak altijd begrip toonde en insprong als ik weer op pad 
ging am te werken aan dit boek. Aan Carla van den Hor, die mij heef! wijs gemaakt in de 
wereld van WP, en vele uren heeft ge-shift-F2 en ge-Ctrl-F4. Aan Addy Kooijrnan, die altijd 
klaar stand am mijn patienten te woord te staan en verder te helpen. 
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